Unnamed: 0 float64 0 700k | Date stringlengths 23 23 | Article_title stringlengths 1 250 | Stock_symbol stringlengths 1 5 | Url stringlengths 44 135 | Publisher float64 | Author float64 | Article stringlengths 1 343k ⌀ | Lsa_summary stringlengths 48 53.9k ⌀ | Luhn_summary stringlengths 1 53.9k ⌀ | Textrank_summary stringlengths 1 53.9k ⌀ | Lexrank_summary stringlengths 1 53.9k ⌀ |
|---|---|---|---|---|---|---|---|---|---|---|---|
23,400 | 2022-05-10 00:00:00 UTC | Noteworthy ETF Outflows: SPY, AAPL, MSFT, ABBV | ABBV | https://www.nasdaq.com/articles/noteworthy-etf-outflows%3A-spy-aapl-msft-abbv | null | null | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the SPDR S&P 500 ETF Trust (Symbol: SPY) where we have detected an approximate $2.4 billion dollar outflow -- that's a 0.7% decrease week over week (from 904,580,000 to 898,630,000). Among the l... | Among the largest underlying components of SPY, in trading today Apple Inc (Symbol: AAPL) is up about 2.2%, Microsoft Corporation (Symbol: MSFT) is up about 2.2%, and AbbVie Inc (Symbol: ABBV) is up by about 1.2%. For a complete list of holdings, visit the SPY Holdings page » The chart below shows the one year price pe... | Among the largest underlying components of SPY, in trading today Apple Inc (Symbol: AAPL) is up about 2.2%, Microsoft Corporation (Symbol: MSFT) is up about 2.2%, and AbbVie Inc (Symbol: ABBV) is up by about 1.2%. For a complete list of holdings, visit the SPY Holdings page » The chart below shows the one year price pe... | Among the largest underlying components of SPY, in trading today Apple Inc (Symbol: AAPL) is up about 2.2%, Microsoft Corporation (Symbol: MSFT) is up about 2.2%, and AbbVie Inc (Symbol: ABBV) is up by about 1.2%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Chann... | Among the largest underlying components of SPY, in trading today Apple Inc (Symbol: AAPL) is up about 2.2%, Microsoft Corporation (Symbol: MSFT) is up about 2.2%, and AbbVie Inc (Symbol: ABBV) is up by about 1.2%. For a complete list of holdings, visit the SPY Holdings page » The chart below shows the one year price pe... |
23,401 | 2022-05-10 00:00:00 UTC | Q1 Earnings Scorecard and Analyst Reports for AbbVie, QUALCOMM & Linde | ABBV | https://www.nasdaq.com/articles/q1-earnings-scorecard-and-analyst-reports-for-abbvie-qualcomm-linde | null | null | Tuesday, May 10, 2022
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features update on the 2022 Q1 earnings season and new research reports on 16 major stocks, including AbbVie Inc. (ABBV), QUALCOMM Incorporated (QCOM), and Linde plc (LIN). These research repor... | Today's Featured Reports Shares of AbbVie have outperformed the Zacks Large Cap Pharmaceuticals industry over the past year (+37.0% vs. +20.5%) on the back of the company's successful label expansion of its cancer drugs, Imbruvica and Venclexta. If you want an email notification each time Sheraz publishes a new article... | Today's Research Daily features update on the 2022 Q1 earnings season and new research reports on 16 major stocks, including AbbVie Inc. (ABBV), QUALCOMM Incorporated (QCOM), and Linde plc (LIN). If you want an email notification each time Sheraz publishes a new article, please click here>>> Today's Must Read AbbVie's ... | Today's Research Daily features update on the 2022 Q1 earnings season and new research reports on 16 major stocks, including AbbVie Inc. (ABBV), QUALCOMM Incorporated (QCOM), and Linde plc (LIN). If you want an email notification each time Sheraz publishes a new article, please click here>>> Today's Must Read AbbVie's ... | If you want an email notification each time Sheraz publishes a new article, please click here>>> Today's Must Read AbbVie's (ABBV) Pipeline & New Drugs Key to Long-Term Growth Qualcomm (QCOM) Rides on 5G Chips, Solid EDGE Traction Linde (LIN) to Gain on Contracts With On-Site Customers Featured Reports Abbott (ABT) Rid... |
23,402 | 2022-05-10 00:00:00 UTC | Reata (RETA) Q1 Earnings Top, Omaveloxolone MAA Likely in Q4 | ABBV | https://www.nasdaq.com/articles/reata-reta-q1-earnings-top-omaveloxolone-maa-likely-in-q4 | null | null | Reata Pharmaceuticals, Inc. RETA reported first-quarter 2022 loss of $2.03 per share, narrower than the Zacks Consensus Estimate of a loss of $2.26.
However, the above loss included stock-based compensation and a non-cash interest expense. Adjusted loss for the quarter was $1.33 per share, wider than the loss of $1.16 ... | Reata had reacquired the development, manufacturing and commercialization rights for omaveloxolone and bardoxolone from AbbVie ABBV in 2019. The company also reacquired ex-U.S. rights to bardoxolone, omaveloxolone and its proprietary Nrf2 product platform from AbbVie during the same time. With this move, Reata is likel... | Reata had reacquired the development, manufacturing and commercialization rights for omaveloxolone and bardoxolone from AbbVie ABBV in 2019. The company also reacquired ex-U.S. rights to bardoxolone, omaveloxolone and its proprietary Nrf2 product platform from AbbVie during the same time. With this move, Reata is likel... | Reata had reacquired the development, manufacturing and commercialization rights for omaveloxolone and bardoxolone from AbbVie ABBV in 2019. The company also reacquired ex-U.S. rights to bardoxolone, omaveloxolone and its proprietary Nrf2 product platform from AbbVie during the same time. With this move, Reata is likel... | Reata had reacquired the development, manufacturing and commercialization rights for omaveloxolone and bardoxolone from AbbVie ABBV in 2019. The company also reacquired ex-U.S. rights to bardoxolone, omaveloxolone and its proprietary Nrf2 product platform from AbbVie during the same time. With this move, Reata is likel... |
23,403 | 2022-05-10 00:00:00 UTC | 6 Undervalued Stocks You Should Buy For the Long Term | ABBV | https://www.nasdaq.com/articles/6-undervalued-stocks-you-should-buy-for-the-long-term | null | null | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
These are the 6 undervalued stocks you should buy for the long term that have low price-to-earnings (P/E) multiples, pay good dividends, and also have share buyback programs.
McDonald’s (MCD): McDonald’s trades with a 2.23% dividend yield, 25x forward earni... | AbbVie (NYSE:ABBV) — A cheap pharmaceutical company with a 3.69% yield and consistent dividend growth. MCD McDonalds $246.57 ALL Allstate $129.78 HPQ HP Inc. $38.14 TGT Target $220.37 ABBV AbbVie $152.60 NRG NRG Energy $41.32 Undervalued Stocks: McDonald’s Corp (MCD) Source: 8th.creator / Shutterstock.com Market Value:... | MCD McDonalds $246.57 ALL Allstate $129.78 HPQ HP Inc. $38.14 TGT Target $220.37 ABBV AbbVie $152.60 NRG NRG Energy $41.32 Undervalued Stocks: McDonald’s Corp (MCD) Source: 8th.creator / Shutterstock.com Market Value: $182 billion McDonald’s Corp (NYSE:MCD) just released strong Q1 earnings on April 28. AbbVie (NYSE:ABB... | MCD McDonalds $246.57 ALL Allstate $129.78 HPQ HP Inc. $38.14 TGT Target $220.37 ABBV AbbVie $152.60 NRG NRG Energy $41.32 Undervalued Stocks: McDonald’s Corp (MCD) Source: 8th.creator / Shutterstock.com Market Value: $182 billion McDonald’s Corp (NYSE:MCD) just released strong Q1 earnings on April 28. AbbVie (NYSE:ABB... | MCD McDonalds $246.57 ALL Allstate $129.78 HPQ HP Inc. $38.14 TGT Target $220.37 ABBV AbbVie $152.60 NRG NRG Energy $41.32 Undervalued Stocks: McDonald’s Corp (MCD) Source: 8th.creator / Shutterstock.com Market Value: $182 billion McDonald’s Corp (NYSE:MCD) just released strong Q1 earnings on April 28. AbbVie (NYSE:ABB... |
23,404 | 2022-05-10 00:00:00 UTC | Walgreens, CVS, Walmart begin $878 million opioid trial in Ohio | ABBV | https://www.nasdaq.com/articles/walgreens-cvs-walmart-begin-%24878-million-opioid-trial-in-ohio | null | null | By Dietrich Knauth
May 10 (Reuters) - CVS Health Corp CVS.N, Walgreens Boots Alliance Inc WBA.O and Walmart Inc WMT.N on Tuesday begin a first-of-its-kind trial to determine what the pharmacy chains owe for their role in the opioid epidemic in two Ohio counties, which are seeking $878 million.
A federal jury decided in... | A New York jury in December found drugmakers Teva Pharmaceutical Industries Ltd TEVA.TA and AbbVie Inc ABBV.N responsible for causing a public nuisance in the state, although the amount they must pay will be determined in a trial later in 2022. By Dietrich Knauth May 10 (Reuters) - CVS Health Corp CVS.N, Walgreens Boot... | A New York jury in December found drugmakers Teva Pharmaceutical Industries Ltd TEVA.TA and AbbVie Inc ABBV.N responsible for causing a public nuisance in the state, although the amount they must pay will be determined in a trial later in 2022. Walgreens, CVS and Walmart countered with an offer of a one-year program to... | A New York jury in December found drugmakers Teva Pharmaceutical Industries Ltd TEVA.TA and AbbVie Inc ABBV.N responsible for causing a public nuisance in the state, although the amount they must pay will be determined in a trial later in 2022. By Dietrich Knauth May 10 (Reuters) - CVS Health Corp CVS.N, Walgreens Boot... | A New York jury in December found drugmakers Teva Pharmaceutical Industries Ltd TEVA.TA and AbbVie Inc ABBV.N responsible for causing a public nuisance in the state, although the amount they must pay will be determined in a trial later in 2022. By Dietrich Knauth May 10 (Reuters) - CVS Health Corp CVS.N, Walgreens Boot... |
23,405 | 2022-05-06 00:00:00 UTC | Ironwood (IRWD) Q1 Earnings Miss, Linzess Growth Continues | ABBV | https://www.nasdaq.com/articles/ironwood-irwd-q1-earnings-miss-linzess-growth-continues | null | null | Ironwood Pharmaceuticals, Inc. IRWD reported first-quarter 2022 adjusted earnings of 21 cents per share, missing the Zacks Consensus Estimate of 27 cents. The company had reported adjusted earnings of 24 cents per share in the year-ago quarter.
Total revenues of $97.5 million beat the Zacks Consensus Estimate of $95.49... | Image Source: Zacks Investment Research Quarter in Detail As reported by partner AbbVie ABBV, Ironwood’s sole marketed product — Linzess (linaclotide) — generated net sales of almost $232.3 million in the United States, up 8% year over year. Ironwood and AbbVie equally share Linzess’ brand collaboration profits or loss... | Image Source: Zacks Investment Research Quarter in Detail As reported by partner AbbVie ABBV, Ironwood’s sole marketed product — Linzess (linaclotide) — generated net sales of almost $232.3 million in the United States, up 8% year over year. Ironwood and AbbVie equally share Linzess’ brand collaboration profits or loss... | Image Source: Zacks Investment Research Quarter in Detail As reported by partner AbbVie ABBV, Ironwood’s sole marketed product — Linzess (linaclotide) — generated net sales of almost $232.3 million in the United States, up 8% year over year. Ironwood and AbbVie equally share Linzess’ brand collaboration profits or loss... | Image Source: Zacks Investment Research Quarter in Detail As reported by partner AbbVie ABBV, Ironwood’s sole marketed product — Linzess (linaclotide) — generated net sales of almost $232.3 million in the United States, up 8% year over year. Ironwood and AbbVie equally share Linzess’ brand collaboration profits or loss... |
23,406 | 2022-05-06 00:00:00 UTC | 7 Defensive Dividend Healthcare Stocks to Buy Now | ABBV | https://www.nasdaq.com/articles/7-defensive-dividend-healthcare-stocks-to-buy-now | null | null | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
Adding defensive healthcare stocks can be a great way to ride out continued volatility in the market.
AbbVie (ABBV): Investors are overreacting to this venerable big pharma company’s recent earnings report.
Amgen (AMGN): An established biotech company with ... | AbbVie (ABBV): Investors are overreacting to this venerable big pharma company’s recent earnings report. ABBV AbbVie $152.84 AMGN Amgen $233.68 BAX Baxter International $72.83 DGX Quest Diagnostics $137.35 HUM Humana $437.23 MRK Merck $87.59 ZTS Zoetis $172.81 Healthcare Stocks: AbbVie (ABBV) Source: Piotr Swat / Shutt... | ABBV AbbVie $152.84 AMGN Amgen $233.68 BAX Baxter International $72.83 DGX Quest Diagnostics $137.35 HUM Humana $437.23 MRK Merck $87.59 ZTS Zoetis $172.81 Healthcare Stocks: AbbVie (ABBV) Source: Piotr Swat / Shutterstock.com As I discussed last month, several developments, along with market-related factors, have knoc... | ABBV AbbVie $152.84 AMGN Amgen $233.68 BAX Baxter International $72.83 DGX Quest Diagnostics $137.35 HUM Humana $437.23 MRK Merck $87.59 ZTS Zoetis $172.81 Healthcare Stocks: AbbVie (ABBV) Source: Piotr Swat / Shutterstock.com As I discussed last month, several developments, along with market-related factors, have knoc... | AbbVie (ABBV): Investors are overreacting to this venerable big pharma company’s recent earnings report. ABBV AbbVie $152.84 AMGN Amgen $233.68 BAX Baxter International $72.83 DGX Quest Diagnostics $137.35 HUM Humana $437.23 MRK Merck $87.59 ZTS Zoetis $172.81 Healthcare Stocks: AbbVie (ABBV) Source: Piotr Swat / Shutt... |
23,407 | 2022-05-05 00:00:00 UTC | June 24th Options Now Available For AbbVie (ABBV) | ABBV | https://www.nasdaq.com/articles/june-24th-options-now-available-for-abbvie-abbv | null | null | Investors in AbbVie Inc (Symbol: ABBV) saw new options begin trading today, for the June 24th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ABBV options chain for the new June 24th contracts and identified one put and one call contract of particular interest.
The put contract a... | Of course, a lot of upside could potentially be left on the table if ABBV shares really soar, which is why looking at the trailing twelve month trading history for AbbVie Inc, as well as studying the business fundamentals becomes important. Below is a chart showing ABBV's trailing twelve month trading history, with the... | Below is a chart showing ABBV's trailing twelve month trading history, with the $155.00 strike highlighted in red: Considering the fact that the $155.00 strike represents an approximate 2% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the pos... | Below is a chart showing the trailing twelve month trading history for AbbVie Inc, and highlighting in green where the $150.00 strike is located relative to that history: Turning to the calls side of the option chain, the call contract at the $155.00 strike price has a current bid of $4.00. Below is a chart showing ABB... | At Stock Options Channel, our YieldBoost formula has looked up and down the ABBV options chain for the new June 24th contracts and identified one put and one call contract of particular interest. Below is a chart showing ABBV's trailing twelve month trading history, with the $155.00 strike highlighted in red: Consideri... |
23,408 | 2022-05-05 00:00:00 UTC | Walgreens reaches $683 mln opioid settlement with Florida | ABBV | https://www.nasdaq.com/articles/walgreens-reaches-%24683-mln-opioid-settlement-with-florida | null | null | By Dietrich Knauth
May 5 (Reuters) - Walgreens Boots Alliance WBA.O said on Thursday it has reached a $683 million settlement with Florida to resolve claims that the pharmacy chain exacerbated an opioid epidemic in the state.
The settlement includes $620 million to be paid to Florida over 18 years, plus $63 million for... | By Dietrich Knauth May 5 (Reuters) - Walgreens Boots Alliance WBA.O said on Thursday it has reached a $683 million settlement with Florida to resolve claims that the pharmacy chain exacerbated an opioid epidemic in the state. It ends a trial that began on April 11, after Walgreens decided not to join a combined $878 mi... | By Dietrich Knauth May 5 (Reuters) - Walgreens Boots Alliance WBA.O said on Thursday it has reached a $683 million settlement with Florida to resolve claims that the pharmacy chain exacerbated an opioid epidemic in the state. It ends a trial that began on April 11, after Walgreens decided not to join a combined $878 mi... | By Dietrich Knauth May 5 (Reuters) - Walgreens Boots Alliance WBA.O said on Thursday it has reached a $683 million settlement with Florida to resolve claims that the pharmacy chain exacerbated an opioid epidemic in the state. The settlement includes $620 million to be paid to Florida over 18 years, plus $63 million for... | By Dietrich Knauth May 5 (Reuters) - Walgreens Boots Alliance WBA.O said on Thursday it has reached a $683 million settlement with Florida to resolve claims that the pharmacy chain exacerbated an opioid epidemic in the state. The settlement includes $620 million to be paid to Florida over 18 years, plus $63 million for... |
23,409 | 2022-05-05 00:00:00 UTC | Here is What to Know Beyond Why AbbVie Inc. (ABBV) is a Trending Stock | ABBV | https://www.nasdaq.com/articles/here-is-what-to-know-beyond-why-abbvie-inc.-abbv-is-a-trending-stock | null | null | AbbVie (ABBV) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.
Over the past month, shares of this drugmaker have returned -10.3%, compared to the Zacks S&P 500 composite's -6.1% change. Du... | Conclusion The facts discussed here and much other information on Zacks.com might help determine whether or not it's worthwhile paying attention to the market buzz about AbbVie. AbbVie (ABBV) is one of the stocks most watched by Zacks.com visitors lately. During this period, the Zacks Large Cap Pharmaceuticals industry... | Last Reported Results and Surprise History AbbVie reported revenues of $13.54 billion in the last reported quarter, representing a year-over-year change of +4.1%. AbbVie (ABBV) is one of the stocks most watched by Zacks.com visitors lately. During this period, the Zacks Large Cap Pharmaceuticals industry, which AbbVie ... | The size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, has resulted in a Zacks Rank #3 (Hold) for AbbVie. AbbVie (ABBV) is one of the stocks most watched by Zacks.com visitors lately. During this period, the Zacks Large Cap Pharmaceuticals industry, which ... | For the next fiscal year, the consensus earnings estimate of $11.84 indicates a change of -15.7% from what AbbVie is expected to report a year ago. AbbVie (ABBV) is one of the stocks most watched by Zacks.com visitors lately. During this period, the Zacks Large Cap Pharmaceuticals industry, which AbbVie falls in, has g... |
23,410 | 2022-05-05 00:00:00 UTC | 3 Top Healthcare Stocks to Buy for May | ABBV | https://www.nasdaq.com/articles/3-top-healthcare-stocks-to-buy-for-may | null | null | Investing in trends that are unlikely to reverse is key to being a successful investor.
A more populous and aging global population is almost a guarantee that quality healthcare stocks will do well over the long haul. That's because healthcare products and services are essential to extended life expectancies, which als... | AbbVie The next stock to consider buying in May is AbbVie (NYSE: ABBV). AbbVie's $270 billion market cap makes it the fourth-largest pharma stock in the world. AbbVie's portfolio contained 13 blockbuster drugs in 2021, including the top-selling drug in the world, Humira. | AbbVie The next stock to consider buying in May is AbbVie (NYSE: ABBV). AbbVie's $270 billion market cap makes it the fourth-largest pharma stock in the world. AbbVie's portfolio contained 13 blockbuster drugs in 2021, including the top-selling drug in the world, Humira. | See the 10 stocks *Stock Advisor returns as of April 7, 2022 Kody Kester has positions in AbbVie and Medtronic. AbbVie The next stock to consider buying in May is AbbVie (NYSE: ABBV). AbbVie's $270 billion market cap makes it the fourth-largest pharma stock in the world. | AbbVie The next stock to consider buying in May is AbbVie (NYSE: ABBV). AbbVie's $270 billion market cap makes it the fourth-largest pharma stock in the world. AbbVie's portfolio contained 13 blockbuster drugs in 2021, including the top-selling drug in the world, Humira. |
23,411 | 2022-05-05 00:00:00 UTC | Pfizer Is Poised to Shatter These 2 Records in 2022 | ABBV | https://www.nasdaq.com/articles/pfizer-is-poised-to-shatter-these-2-records-in-2022 | null | null | Pfizer (NYSE: PFE) just delivered the best quarter in the company's history. Its first-quarter revenue topped $25.6 billion. Adjusted profits totaled more than $9.3 billion.
The drugmaker isn't done yet. And it's likely to go beyond notching wins against its own historical performance. Pfizer is poised to shatter these... | Currently, AbbVie's (NYSE: ABBV) Humira reigns as the world's best-selling non-vaccine drug. See the 10 stocks *Stock Advisor returns as of April 7, 2022 Keith Speights has positions in AbbVie and Pfizer. While pharmaceuticals ranked as the healthcare giant's top moneymaker, its consumer health and medical device segme... | Currently, AbbVie's (NYSE: ABBV) Humira reigns as the world's best-selling non-vaccine drug. See the 10 stocks *Stock Advisor returns as of April 7, 2022 Keith Speights has positions in AbbVie and Pfizer. Best-selling non-vaccine drug ever Pfizer's Comirnaty already holds the title as the best-selling drug in a single ... | Currently, AbbVie's (NYSE: ABBV) Humira reigns as the world's best-selling non-vaccine drug. See the 10 stocks *Stock Advisor returns as of April 7, 2022 Keith Speights has positions in AbbVie and Pfizer. Most revenue for a pharma company Thanks in large part to the anticipated surge in sales for Paxlovid, Pfizer is al... | Currently, AbbVie's (NYSE: ABBV) Humira reigns as the world's best-selling non-vaccine drug. See the 10 stocks *Stock Advisor returns as of April 7, 2022 Keith Speights has positions in AbbVie and Pfizer. That broke the previous record of single-year sales for a non-vaccine drug of $19.8 billion set by Humira in 2020. |
23,412 | 2022-05-05 00:00:00 UTC | This Stock Is Trouncing the Market in 2022 -- and Its Prospects Just Got Even Better | ABBV | https://www.nasdaq.com/articles/this-stock-is-trouncing-the-market-in-2022-and-its-prospects-just-got-even-better | null | null | It's hard to swim against the current, and investors these days definitely find the current going against them. Most stocks have fallen, with the S&P 500 index in correction territory and the Nasdaq Composite index in bear territory again.
However, not every stock is being swept in the wrong direction. Here's one that'... | AbbVie (NYSE: ABBV) announced in its first-quarter conference call last Friday that it's throwing in the towel on developing a triplet therapy for treating CF. Hudson added that AbbVie hopes to advance a new triple combo into phase 2 testing by early 2023. And with the latest news from AbbVie, Vertex's CF monopoly is s... | And with the latest news from AbbVie, Vertex's CF monopoly is stronger than ever. AbbVie (NYSE: ABBV) announced in its first-quarter conference call last Friday that it's throwing in the towel on developing a triplet therapy for treating CF. Hudson added that AbbVie hopes to advance a new triple combo into phase 2 test... | See the 10 stocks *Stock Advisor returns as of April 7, 2022 Keith Speights has positions in AbbVie and Vertex Pharmaceuticals. AbbVie (NYSE: ABBV) announced in its first-quarter conference call last Friday that it's throwing in the towel on developing a triplet therapy for treating CF. Hudson added that AbbVie hopes t... | AbbVie (NYSE: ABBV) announced in its first-quarter conference call last Friday that it's throwing in the towel on developing a triplet therapy for treating CF. Hudson added that AbbVie hopes to advance a new triple combo into phase 2 testing by early 2023. And with the latest news from AbbVie, Vertex's CF monopoly is s... |
23,413 | 2022-05-04 00:00:00 UTC | These Warren Buffett Dividend Stocks Can Make You $12,800 in Passive Income | ABBV | https://www.nasdaq.com/articles/these-warren-buffett-dividend-stocks-can-make-you-%2412800-in-passive-income | null | null | If anyone knows that it takes money to make money, it's Warren Buffett. But the longtime Berkshire Hathaway (NYSE: BRK.A) (NYSE: BRK.B) CEO also knows that making significant passive income is actually easy if you have enough to invest in the right stocks.
Some great stock ideas can be found right in Berkshire's own po... | In particular, AbbVie appears to be in a solid position to quickly rebound from the loss of U.S. exclusivity for top-selling Humira next year. AbbVie If you've been keeping track, Store Capital and Chevron together could generate at least $9,000 in passive income per year. Investing another $100,000 in AbbVie (NYSE: AB... | AbbVie If you've been keeping track, Store Capital and Chevron together could generate at least $9,000 in passive income per year. Investing another $100,000 in AbbVie (NYSE: ABBV) would add another $3,840, bringing the total to $12,840. AbbVie's dividend is as dependable as they come. | See the 10 stocks *Stock Advisor returns as of April 7, 2022 Keith Speights has positions in AbbVie and Berkshire Hathaway (B shares). AbbVie If you've been keeping track, Store Capital and Chevron together could generate at least $9,000 in passive income per year. Investing another $100,000 in AbbVie (NYSE: ABBV) woul... | AbbVie If you've been keeping track, Store Capital and Chevron together could generate at least $9,000 in passive income per year. See the 10 stocks *Stock Advisor returns as of April 7, 2022 Keith Speights has positions in AbbVie and Berkshire Hathaway (B shares). Investing another $100,000 in AbbVie (NYSE: ABBV) woul... |
23,414 | 2022-05-02 00:00:00 UTC | Is First Trust Health Care AlphaDEX ETF (FXH) a Strong ETF Right Now? | ABBV | https://www.nasdaq.com/articles/is-first-trust-health-care-alphadex-etf-fxh-a-strong-etf-right-now-1 | null | null | Designed to provide broad exposure to the Health Care ETFs category of the market, the First Trust Health Care AlphaDEX ETF (FXH) is a smart beta exchange traded fund launched on 05/08/2007.
What Are Smart Beta ETFs?
Market cap weighted indexes were created to reflect the market, or a specific segment of the market, an... | When you look at individual holdings, Abbvie Inc. (ABBV) accounts for about 2.47% of the fund's total assets, followed by Universal Health Services, Inc. (class B) (UHS) and Regeneron Pharmaceuticals, Inc. (REGN). AbbVie Inc. (ABBV): Free Stock Analysis Report And, cheaper funds can significantly outperform their more ... | When you look at individual holdings, Abbvie Inc. (ABBV) accounts for about 2.47% of the fund's total assets, followed by Universal Health Services, Inc. (class B) (UHS) and Regeneron Pharmaceuticals, Inc. (REGN). AbbVie Inc. (ABBV): Free Stock Analysis Report Vanguard Health Care ETF (VHT) tracks MSCI US Investable Ma... | When you look at individual holdings, Abbvie Inc. (ABBV) accounts for about 2.47% of the fund's total assets, followed by Universal Health Services, Inc. (class B) (UHS) and Regeneron Pharmaceuticals, Inc. (REGN). AbbVie Inc. (ABBV): Free Stock Analysis Report Designed to provide broad exposure to the Health Care ETFs ... | When you look at individual holdings, Abbvie Inc. (ABBV) accounts for about 2.47% of the fund's total assets, followed by Universal Health Services, Inc. (class B) (UHS) and Regeneron Pharmaceuticals, Inc. (REGN). AbbVie Inc. (ABBV): Free Stock Analysis Report Designed to provide broad exposure to the Health Care ETFs ... |
23,415 | 2022-04-30 00:00:00 UTC | AbbVie's Q1 Good News That Investors Could Be Missing | ABBV | https://www.nasdaq.com/articles/abbvies-q1-good-news-that-investors-could-be-missing | null | null | The first-quarter results AbbVie (NYSE: ABBV) delivered before the market opened Friday were disappointing in several ways. The drugmaker's revenue of $13.5 billion undershot the consensus Wall Street estimate of $13.6 billion, and management also lowered its full-year adjusted earnings guidance.
The pharma stock slid ... | AbbVie's post-Humira strategy is already working The long-anticipated loss of U.S. exclusivity for Humira, its top-selling drug, will become a reality next year. But AbbVie also planned to preserve its dominance in the immunology market even as its revenues from Humira fade due to biosimilar competition. The first-quar... | When AbbVie incurs milestone expenses, it means that clinical studies have gone well or that regulatory decisions have been favorable. AbbVie's Allergan acquisition is accomplishing its goals AbbVie acquired Allergan in 2020. The first-quarter results AbbVie (NYSE: ABBV) delivered before the market opened Friday were d... | AbbVie's Allergan acquisition is accomplishing its goals AbbVie acquired Allergan in 2020. See the 10 stocks *Stock Advisor returns as of April 7, 2022 Keith Speights has positions in AbbVie. The first-quarter results AbbVie (NYSE: ABBV) delivered before the market opened Friday were disappointing in several ways. | AbbVie's Allergan acquisition is accomplishing its goals AbbVie acquired Allergan in 2020. The first-quarter results AbbVie (NYSE: ABBV) delivered before the market opened Friday were disappointing in several ways. However, AbbVie did narrowly beat analysts' earnings expectations. |
23,416 | 2022-04-30 00:00:00 UTC | AbbVie (ABBV) Q1 2022 Earnings Call Transcript | ABBV | https://www.nasdaq.com/articles/abbvie-abbv-q1-2022-earnings-call-transcript | null | null | Image source: The Motley Fool.
AbbVie (NYSE: ABBV)
Q1 2022 Earnings Call
Apr 29, 2022, 9:00 a.m. ET
Contents:
Prepared Remarks
Questions and Answers
Call Participants
Prepared Remarks:
Operator
Good morning, and thank you for standing by. Welcome to the AbbVie first quarter 2022earnings conference call [Operator instr... | Based on the magnitude of clinical data and real-world evidence generated for Imbruvica, showing sustained disease control, as well as overall patient survival, we are confident it will continue to be a meaningful product for AbbVie over the long term. AbbVie (NYSE: ABBV) Q1 2022 Earnings Call Apr 29, 2022, 9:00 a.m. W... | Operator [Operator signoff] Duration: 74 minutes Call participants: Liz Shea -- Vice President of Investor Relations Rick Gonzalez -- Chairman of the Board and Chief Executive Officer Jeff Stewart -- Executive Vice President, Commercial Operations Tom Hudson -- Senior Vice President, Research and Development and Chief ... | Carrie Strom -- Senior Vice President, AbbVie, and President, Global Allergan Aesthetics Gary, this is Carrie Strom, president of global allergen aesthetics, and I'll take your question about the aesthetics market. Operator [Operator signoff] Duration: 74 minutes Call participants: Liz Shea -- Vice President of Investo... | Operator [Operator signoff] Duration: 74 minutes Call participants: Liz Shea -- Vice President of Investor Relations Rick Gonzalez -- Chairman of the Board and Chief Executive Officer Jeff Stewart -- Executive Vice President, Commercial Operations Tom Hudson -- Senior Vice President, Research and Development and Chief ... |
23,417 | 2022-04-30 00:00:00 UTC | FDA Approves AbbVie's Rinvoq To Treatment Active Ankylosing Spondylitis | ABBV | https://www.nasdaq.com/articles/fda-approves-abbvies-rinvoq-to-treatment-active-ankylosing-spondylitis | null | null | (RTTNews) - The U.S. Food and Drug Administration has approved AbbVie's (ABBV) Rinvoq (upadacitinib; 15 mg, once daily) for the treatment of adults with active ankylosing spondylitis who have had an inadequate response or intolerance to one or more tumor necrosis factor blockers.
The FDA approval was supported by effic... | (RTTNews) - The U.S. Food and Drug Administration has approved AbbVie's (ABBV) Rinvoq (upadacitinib; 15 mg, once daily) for the treatment of adults with active ankylosing spondylitis who have had an inadequate response or intolerance to one or more tumor necrosis factor blockers. The FDA approval was supported by effic... | (RTTNews) - The U.S. Food and Drug Administration has approved AbbVie's (ABBV) Rinvoq (upadacitinib; 15 mg, once daily) for the treatment of adults with active ankylosing spondylitis who have had an inadequate response or intolerance to one or more tumor necrosis factor blockers. The FDA approval was supported by effic... | (RTTNews) - The U.S. Food and Drug Administration has approved AbbVie's (ABBV) Rinvoq (upadacitinib; 15 mg, once daily) for the treatment of adults with active ankylosing spondylitis who have had an inadequate response or intolerance to one or more tumor necrosis factor blockers. The FDA approval was supported by effic... | (RTTNews) - The U.S. Food and Drug Administration has approved AbbVie's (ABBV) Rinvoq (upadacitinib; 15 mg, once daily) for the treatment of adults with active ankylosing spondylitis who have had an inadequate response or intolerance to one or more tumor necrosis factor blockers. The FDA approval was supported by effic... |
23,418 | 2022-04-29 00:00:00 UTC | AbbVie Shares Hurt On Reduced Earnings Outlook | ABBV | https://www.nasdaq.com/articles/abbvie-shares-hurt-on-reduced-earnings-outlook | null | null | (RTTNews) - Shares of biopharmaceutical company AbbVie Inc. (ABBV) are down more than 8% after the company reduced its annual earnings outlook. Its first-quarter sales also missed analysts' view.
The company cut its annual EPS outlook to $13.92 - $14.12 from $14.00 - $14.20 citing a $0.08 per share impact related to th... | (RTTNews) - Shares of biopharmaceutical company AbbVie Inc. (ABBV) are down more than 8% after the company reduced its annual earnings outlook. ABBV is at $143.10 currently. The company cut its annual EPS outlook to $13.92 - $14.12 from $14.00 - $14.20 citing a $0.08 per share impact related to the acquired IPR&D and m... | (RTTNews) - Shares of biopharmaceutical company AbbVie Inc. (ABBV) are down more than 8% after the company reduced its annual earnings outlook. ABBV is at $143.10 currently. Its first-quarter sales also missed analysts' view. | (RTTNews) - Shares of biopharmaceutical company AbbVie Inc. (ABBV) are down more than 8% after the company reduced its annual earnings outlook. ABBV is at $143.10 currently. The company cut its annual EPS outlook to $13.92 - $14.12 from $14.00 - $14.20 citing a $0.08 per share impact related to the acquired IPR&D and m... | (RTTNews) - Shares of biopharmaceutical company AbbVie Inc. (ABBV) are down more than 8% after the company reduced its annual earnings outlook. ABBV is at $143.10 currently. Its first-quarter sales also missed analysts' view. |
23,419 | 2022-04-29 00:00:00 UTC | Why AbbVie's Shares Dropped 10.5% Friday | ABBV | https://www.nasdaq.com/articles/why-abbvies-shares-dropped-10.5-friday | null | null | What happened
Pharmaceutical company AbbVie (NYSE: ABBV) saw its shares drop 10.5% on Friday. The stock closed at $156.31 on Thursday, then opened on Friday at $149.56 and fell to a low of $139.93 in early morning trading before rallying a bit in the afternoon.
The stock's 52-week low is $105.56 with a 52-week high of ... | The bad news was AbbVie reported lower sales of cancer drug Imbruvica and immunology stalwart Humira, thanks to competition from newer therapies. What happened Pharmaceutical company AbbVie (NYSE: ABBV) saw its shares drop 10.5% on Friday. AbbVie reported $1.1 billion in sales for the drug, down 7.4%. | The bad news was AbbVie reported lower sales of cancer drug Imbruvica and immunology stalwart Humira, thanks to competition from newer therapies. What happened Pharmaceutical company AbbVie (NYSE: ABBV) saw its shares drop 10.5% on Friday. AbbVie reported $1.1 billion in sales for the drug, down 7.4%. | What happened Pharmaceutical company AbbVie (NYSE: ABBV) saw its shares drop 10.5% on Friday. The bad news was AbbVie reported lower sales of cancer drug Imbruvica and immunology stalwart Humira, thanks to competition from newer therapies. AbbVie reported $1.1 billion in sales for the drug, down 7.4%. | * They just revealed what they believe are the ten best stocks for investors to buy right now... and AbbVie wasn't one of them! See the 10 stocks *Stock Advisor returns as of April 7, 2022 Jim Halley has positions in AbbVie. What happened Pharmaceutical company AbbVie (NYSE: ABBV) saw its shares drop 10.5% on Friday. |
23,420 | 2022-04-29 00:00:00 UTC | Health Care Sector Update for 04/29/2022: RMD,ABBV,FNCH,ZYME | ABBV | https://www.nasdaq.com/articles/health-care-sector-update-for-04-29-2022%3A-rmdabbvfnchzyme | null | null | Health care stocks were mostly lower this afternoon, with the NYSE Health Care Index sinking 2.0% and the SPDR Health Care Select Sector ETF (XLV) down 2.1%.
The Nasdaq Biotechnology index was retreating 1.7%.
In company news, ResMed (RMD) slipped 6.3% after the medical devices company overnight reported non-GAAP net i... | AbbVie (ABBV) dropped 7.2% after the drugmaker cut its FY22 earnings outlook by $0.08 per share on both sides of its previous guidance to a new range looking for non-GAAP net income in a range of $13.92 to $14.12 from previous projections of $14 to $14.20 per share. Analysts polled by Capital IQ, on average, are expect... | AbbVie (ABBV) dropped 7.2% after the drugmaker cut its FY22 earnings outlook by $0.08 per share on both sides of its previous guidance to a new range looking for non-GAAP net income in a range of $13.92 to $14.12 from previous projections of $14 to $14.20 per share. Analysts polled by Capital IQ, on average, are expect... | AbbVie (ABBV) dropped 7.2% after the drugmaker cut its FY22 earnings outlook by $0.08 per share on both sides of its previous guidance to a new range looking for non-GAAP net income in a range of $13.92 to $14.12 from previous projections of $14 to $14.20 per share. Analysts polled by Capital IQ, on average, are expect... | AbbVie (ABBV) dropped 7.2% after the drugmaker cut its FY22 earnings outlook by $0.08 per share on both sides of its previous guidance to a new range looking for non-GAAP net income in a range of $13.92 to $14.12 from previous projections of $14 to $14.20 per share. Analysts polled by Capital IQ, on average, are expect... |
23,421 | 2022-04-29 00:00:00 UTC | Notable Friday Option Activity: ABBV, CBOE, EXPE | ABBV | https://www.nasdaq.com/articles/notable-friday-option-activity%3A-abbv-cboe-expe | null | null | Among the underlying components of the S&P 500 index, we saw noteworthy options trading volume today in AbbVie Inc (Symbol: ABBV), where a total of 59,816 contracts have traded so far, representing approximately 6.0 million underlying shares. That amounts to about 73.7% of ABBV's average daily trading volume over the p... | Particularly high volume was seen for the $150 strike put option expiring April 29, 2022, with 6,132 contracts trading so far today, representing approximately 613,200 underlying shares of ABBV. Among the underlying components of the S&P 500 index, we saw noteworthy options trading volume today in AbbVie Inc (Symbol: A... | Below is a chart showing ABBV's trailing twelve month trading history, with the $150 strike highlighted in orange: Cboe Global Markets Inc (Symbol: CBOE) saw options trading volume of 4,337 contracts, representing approximately 433,700 underlying shares or approximately 63% of CBOE's average daily trading volume over t... | Among the underlying components of the S&P 500 index, we saw noteworthy options trading volume today in AbbVie Inc (Symbol: ABBV), where a total of 59,816 contracts have traded so far, representing approximately 6.0 million underlying shares. Below is a chart showing ABBV's trailing twelve month trading history, with t... | Among the underlying components of the S&P 500 index, we saw noteworthy options trading volume today in AbbVie Inc (Symbol: ABBV), where a total of 59,816 contracts have traded so far, representing approximately 6.0 million underlying shares. Below is a chart showing ABBV's trailing twelve month trading history, with t... |
23,422 | 2022-04-29 00:00:00 UTC | Technology Sector Update for 04/29/2022: ABBV,FNCH,ZYME | ABBV | https://www.nasdaq.com/articles/technology-sector-update-for-04-29-2022%3A-abbvfnchzyme | null | null | Health care stocks were mostly lower this afternoon, with the NYSE Health Care Index sinking 1.7% and the SPDR Health Care Select Sector ETF (XLV) down 1.9%.
The Nasdaq Biotechnology index was retreating 0.8%.
In company news, AbbVie (ABBV) dropped 8.7% after the drugmaker cut its FY22 earnings outlook by $0.08 per sha... | In company news, AbbVie (ABBV) dropped 8.7% after the drugmaker cut its FY22 earnings outlook by $0.08 per share on both sides of its previous guidance to a new range looking for non-GAAP net income in a range of $13.92 to $14.12 from previous projections of $14 to $14.20 per share. Analysts polled by Capital IQ, on av... | Analysts polled by Capital IQ, on average, are expecting AbbVie to earn $14.17 per share this year, excluding one-time items. In company news, AbbVie (ABBV) dropped 8.7% after the drugmaker cut its FY22 earnings outlook by $0.08 per share on both sides of its previous guidance to a new range looking for non-GAAP net in... | In company news, AbbVie (ABBV) dropped 8.7% after the drugmaker cut its FY22 earnings outlook by $0.08 per share on both sides of its previous guidance to a new range looking for non-GAAP net income in a range of $13.92 to $14.12 from previous projections of $14 to $14.20 per share. Analysts polled by Capital IQ, on av... | In company news, AbbVie (ABBV) dropped 8.7% after the drugmaker cut its FY22 earnings outlook by $0.08 per share on both sides of its previous guidance to a new range looking for non-GAAP net income in a range of $13.92 to $14.12 from previous projections of $14 to $14.20 per share. Analysts polled by Capital IQ, on av... |
23,423 | 2022-04-29 00:00:00 UTC | Health Care Sector Update for 04/29/2022: LNTH, NVO, ABBV, XLV, IBB | ABBV | https://www.nasdaq.com/articles/health-care-sector-update-for-04-29-2022%3A-lnth-nvo-abbv-xlv-ibb | null | null | Health care stocks were mixed premarket Friday. The Health Care SPDR (XLV) was down 0.83%, and the iShares NASDAQ Biotechnology Index (IBB) was recently inactive.
Lantheus Holdings (LNTH) was gaining more than 16% after it reported Q1 adjusted earnings of $0.97 per diluted share, up from $0.05 a year earlier. Four anal... | AbbVie (ABBV) reported Q1 adjusted EPS of $3.16, up from $2.89 a year earlier. AbbVie was recently down more than 4%. The Health Care SPDR (XLV) was down 0.83%, and the iShares NASDAQ Biotechnology Index (IBB) was recently inactive. | AbbVie (ABBV) reported Q1 adjusted EPS of $3.16, up from $2.89 a year earlier. AbbVie was recently down more than 4%. Four analysts polled by Capital IQ expected normalized EPS of $0.46. | AbbVie (ABBV) reported Q1 adjusted EPS of $3.16, up from $2.89 a year earlier. AbbVie was recently down more than 4%. The Health Care SPDR (XLV) was down 0.83%, and the iShares NASDAQ Biotechnology Index (IBB) was recently inactive. | AbbVie (ABBV) reported Q1 adjusted EPS of $3.16, up from $2.89 a year earlier. AbbVie was recently down more than 4%. The Health Care SPDR (XLV) was down 0.83%, and the iShares NASDAQ Biotechnology Index (IBB) was recently inactive. |
23,424 | 2022-04-29 00:00:00 UTC | AbbVie misses quarterly sales expectations on Humira competition | ABBV | https://www.nasdaq.com/articles/abbvie-misses-quarterly-sales-expectations-on-humira-competition | null | null | By Manas Mishra
April 29 (Reuters) - AbbVie Inc ABBV.N missed Wall Street estimates for first-quarter sales on Friday, hurt by European competition for its blockbuster rheumatoid arthritis drug Humira and lower-than-expected revenue from its newer drug Rinvoq.
Shares of Illinois-based Abbvie fell 4.3% to $159.30 before... | Last year, AbbVie completed its $63 billion purchase of Botox-maker Allergan, a move to diversify its portfolio ahead of Humira's loss of exclusivity. By Manas Mishra April 29 (Reuters) - AbbVie Inc ABBV.N missed Wall Street estimates for first-quarter sales on Friday, hurt by European competition for its blockbuster r... | By Manas Mishra April 29 (Reuters) - AbbVie Inc ABBV.N missed Wall Street estimates for first-quarter sales on Friday, hurt by European competition for its blockbuster rheumatoid arthritis drug Humira and lower-than-expected revenue from its newer drug Rinvoq. Shares of Illinois-based Abbvie fell 4.3% to $159.30 before... | By Manas Mishra April 29 (Reuters) - AbbVie Inc ABBV.N missed Wall Street estimates for first-quarter sales on Friday, hurt by European competition for its blockbuster rheumatoid arthritis drug Humira and lower-than-expected revenue from its newer drug Rinvoq. AbbVie has been hoping that sales of its other rheumatoid a... | Net revenues of $13.54 billion missed Refinitiv IBES estimates of $13.61 billion, but beat AbbVie's own target of $13.50 billion. AbbVie lowered its adjusted earnings per share forecast to between $13.92 and $14.12, from earlier estimates of $14.00 to $14.20, citing the impact of those expenses. By Manas Mishra April 2... |
23,425 | 2022-04-29 00:00:00 UTC | AbbVie (ABBV) Tops Q1 Earnings Estimates | ABBV | https://www.nasdaq.com/articles/abbvie-abbv-tops-q1-earnings-estimates | null | null | AbbVie (ABBV) came out with quarterly earnings of $3.16 per share, beating the Zacks Consensus Estimate of $3.15 per share. This compares to earnings of $2.95 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of 0.32%. A quarter ago, it was e... | AbbVie (ABBV) came out with quarterly earnings of $3.16 per share, beating the Zacks Consensus Estimate of $3.15 per share. AbbVie, which belongs to the Zacks Large Cap Pharmaceuticals industry, posted revenues of $13.54 billion for the quarter ended March 2022, missing the Zacks Consensus Estimate by 0.09%. AbbVie sha... | AbbVie, which belongs to the Zacks Large Cap Pharmaceuticals industry, posted revenues of $13.54 billion for the quarter ended March 2022, missing the Zacks Consensus Estimate by 0.09%. AbbVie (ABBV) came out with quarterly earnings of $3.16 per share, beating the Zacks Consensus Estimate of $3.15 per share. AbbVie sha... | AbbVie (ABBV) came out with quarterly earnings of $3.16 per share, beating the Zacks Consensus Estimate of $3.15 per share. AbbVie, which belongs to the Zacks Large Cap Pharmaceuticals industry, posted revenues of $13.54 billion for the quarter ended March 2022, missing the Zacks Consensus Estimate by 0.09%. AbbVie sha... | AbbVie (ABBV) came out with quarterly earnings of $3.16 per share, beating the Zacks Consensus Estimate of $3.15 per share. AbbVie, which belongs to the Zacks Large Cap Pharmaceuticals industry, posted revenues of $13.54 billion for the quarter ended March 2022, missing the Zacks Consensus Estimate by 0.09%. AbbVie sha... |
23,426 | 2022-04-29 00:00:00 UTC | AbbVie Q1 Income Rises | ABBV | https://www.nasdaq.com/articles/abbvie-q1-income-rises | null | null | (RTTNews) - AbbVie (ABBV) released a profit for its first quarter that increased from the same period last year
The company's earnings totaled $4.49 billion, or $2.51 per share. This compares with $3.55 billion, or $1.99 per share, in last year's first quarter.
Excluding items, AbbVie reported adjusted earnings of $5.6... | (RTTNews) - AbbVie (ABBV) released a profit for its first quarter that increased from the same period last year The company's earnings totaled $4.49 billion, or $2.51 per share. Excluding items, AbbVie reported adjusted earnings of $5.64 billion or $3.16 per share for the period. AbbVie earnings at a glance (GAAP) : -E... | (RTTNews) - AbbVie (ABBV) released a profit for its first quarter that increased from the same period last year The company's earnings totaled $4.49 billion, or $2.51 per share. Excluding items, AbbVie reported adjusted earnings of $5.64 billion or $3.16 per share for the period. AbbVie earnings at a glance (GAAP) : -E... | (RTTNews) - AbbVie (ABBV) released a profit for its first quarter that increased from the same period last year The company's earnings totaled $4.49 billion, or $2.51 per share. Excluding items, AbbVie reported adjusted earnings of $5.64 billion or $3.16 per share for the period. AbbVie earnings at a glance (GAAP) : -E... | AbbVie earnings at a glance (GAAP) : -Earnings (Q1): $4.49 Bln. (RTTNews) - AbbVie (ABBV) released a profit for its first quarter that increased from the same period last year The company's earnings totaled $4.49 billion, or $2.51 per share. Excluding items, AbbVie reported adjusted earnings of $5.64 billion or $3.16 p... |
23,427 | 2022-04-29 00:00:00 UTC | AbbVie Trims FY22 Adj. EPS Outlook - Update | ABBV | https://www.nasdaq.com/articles/abbvie-trims-fy22-adj.-eps-outlook-update | null | null | (RTTNews) - While reporting financial results for the first quarter on Friday, biopharmaceutical company AbbVie Inc. (ABBV) trimmed its adjusted earnings guidance for the full-year 2022.
For fiscal 2022, AbbVie now projects adjusted earnings in a range of $13.92 to $14.12 per share, which includes an unfavorable impact... | (RTTNews) - While reporting financial results for the first quarter on Friday, biopharmaceutical company AbbVie Inc. (ABBV) trimmed its adjusted earnings guidance for the full-year 2022. For fiscal 2022, AbbVie now projects adjusted earnings in a range of $13.92 to $14.12 per share, which includes an unfavorable impact... | (RTTNews) - While reporting financial results for the first quarter on Friday, biopharmaceutical company AbbVie Inc. (ABBV) trimmed its adjusted earnings guidance for the full-year 2022. For fiscal 2022, AbbVie now projects adjusted earnings in a range of $13.92 to $14.12 per share, which includes an unfavorable impact... | (RTTNews) - While reporting financial results for the first quarter on Friday, biopharmaceutical company AbbVie Inc. (ABBV) trimmed its adjusted earnings guidance for the full-year 2022. For fiscal 2022, AbbVie now projects adjusted earnings in a range of $13.92 to $14.12 per share, which includes an unfavorable impact... | For fiscal 2022, AbbVie now projects adjusted earnings in a range of $13.92 to $14.12 per share, which includes an unfavorable impact of $0.08 per share related to the acquired IPR&D and milestones expense incurred during the first quarter 2022. (RTTNews) - While reporting financial results for the first quarter on Fri... |
23,428 | 2022-04-29 00:00:00 UTC | AbbVie misses quarterly sales estimates as Humira rivals bite | ABBV | https://www.nasdaq.com/articles/abbvie-misses-quarterly-sales-estimates-as-humira-rivals-bite | null | null | April 29 (Reuters) - AbbVie Inc ABBV.N missed Wall Street estimates for first-quarter sales on Friday, hurt by European competition for its blockbuster rheumatoid arthritis drug Humira and lower-than-expected revenue from its newer drug Rinvoq.
Sales of the world's best selling drug, Humira, fell 2.7% to $4.74 billion ... | Last year, AbbVie completed its $63 billion purchase of Botox-maker Allergan, a move meant to diversify its portfolio ahead of Humira's loss of exclusivity in 2023. AbbVie lowered its adjusted earnings per share forecast to between $13.92 and $14.12, from earlier estimates of $14.00 to $14.20, citing a hit from upfront... | April 29 (Reuters) - AbbVie Inc ABBV.N missed Wall Street estimates for first-quarter sales on Friday, hurt by European competition for its blockbuster rheumatoid arthritis drug Humira and lower-than-expected revenue from its newer drug Rinvoq. AbbVie has been hoping that peak sales of its other rheumatoid arthritis dr... | April 29 (Reuters) - AbbVie Inc ABBV.N missed Wall Street estimates for first-quarter sales on Friday, hurt by European competition for its blockbuster rheumatoid arthritis drug Humira and lower-than-expected revenue from its newer drug Rinvoq. AbbVie has been hoping that peak sales of its other rheumatoid arthritis dr... | April 29 (Reuters) - AbbVie Inc ABBV.N missed Wall Street estimates for first-quarter sales on Friday, hurt by European competition for its blockbuster rheumatoid arthritis drug Humira and lower-than-expected revenue from its newer drug Rinvoq. Net revenues of $13.54 billion missed Refinitiv IBES estimates of $13.61 bi... |
23,429 | 2022-04-29 00:00:00 UTC | The 3 Best ETFs for Dividends | ABBV | https://www.nasdaq.com/articles/the-3-best-etfs-for-dividends-0 | null | null | If you're wishing you had a little more exposure to income investments right now and a little less exposure to growth, you're not alone. The market's recent shellacking hasn't exactly been uniform; growth stocks have really taken it on the chin. And their sell-off may not be over yet.
The good news is, it's not too lat... | Among its top holdings right now are names like AbbVie, JPMorgan Chase, and Verizon, supporting the fund's current yield of around 3.2%. This fund is meant to mirror the Morningstar Dividend Yield Focus Index, which limits its constituents to U.S. stocks "screened for superior company quality and financial health." The... | Among its top holdings right now are names like AbbVie, JPMorgan Chase, and Verizon, supporting the fund's current yield of around 3.2%. iShares High Dividend Equity Fund If your goal is producing above-average dividend income right now, your first stop should arguably be the iShares High Dividend Equity Fund (NYSEMKT:... | Among its top holdings right now are names like AbbVie, JPMorgan Chase, and Verizon, supporting the fund's current yield of around 3.2%. iShares High Dividend Equity Fund If your goal is producing above-average dividend income right now, your first stop should arguably be the iShares High Dividend Equity Fund (NYSEMKT:... | Among its top holdings right now are names like AbbVie, JPMorgan Chase, and Verizon, supporting the fund's current yield of around 3.2%. iShares High Dividend Equity Fund If your goal is producing above-average dividend income right now, your first stop should arguably be the iShares High Dividend Equity Fund (NYSEMKT:... |
23,430 | 2022-04-28 00:00:00 UTC | XRP vs. AbbVie: Price Relationship Crosses Threshold | ABBV | https://www.nasdaq.com/articles/xrp-vs.-abbvie%3A-price-relationship-crosses-threshold | null | null | Here at CryptocurrenciesChannel.com, we find it interesting to track various ETF and stock prices versus various digital assets over time.
We noticed that as of 4/28/2022, XRP ($XRP) can buy you the least amount of AbbVie shares, in the past year. For example, if you had 100 XRP coins and wished to buy shares of ABBV(S... | Note that any stock splits and/or dividends are included when we calculate the ABBV returns. We noticed that as of 4/28/2022, XRP ($XRP) can buy you the least amount of AbbVie shares, in the past year. For example, if you had 100 XRP coins and wished to buy shares of ABBV(Symbol: ABBV) with the proceeds, you would only... | We noticed that as of 4/28/2022, XRP ($XRP) can buy you the least amount of AbbVie shares, in the past year. For example, if you had 100 XRP coins and wished to buy shares of ABBV(Symbol: ABBV) with the proceeds, you would only be able to buy 0.41 share of ABBV. Here's how this relationship looks charted, over the past... | We noticed that as of 4/28/2022, XRP ($XRP) can buy you the least amount of AbbVie shares, in the past year. For example, if you had 100 XRP coins and wished to buy shares of ABBV(Symbol: ABBV) with the proceeds, you would only be able to buy 0.41 share of ABBV. Here's how this relationship looks charted, over the past... | We noticed that as of 4/28/2022, XRP ($XRP) can buy you the least amount of AbbVie shares, in the past year. For example, if you had 100 XRP coins and wished to buy shares of ABBV(Symbol: ABBV) with the proceeds, you would only be able to buy 0.41 share of ABBV. Here's how this relationship looks charted, over the past... |
23,431 | 2022-04-28 00:00:00 UTC | Pre-Market Earnings Report for April 29, 2022 : XOM, CVX, ABBV, AZN, BMY, HON, CHTR, CL, AON, TRP, PSX, LYB | ABBV | https://www.nasdaq.com/articles/pre-market-earnings-report-for-april-29-2022-%3A-xom-cvx-abbv-azn-bmy-hon-chtr-cl-aon-trp | null | null | The following companies are expected to report earnings prior to market open on 04/29/2022. Visit our Earnings Calendar for a full list of expected earnings releases.
Exxon Mobil Corporation (XOM)is reporting for the quarter ending March 31, 2022. The oil company's consensus earnings per share forecast from the 7 anal... | AbbVie Inc. (ABBV)is reporting for the quarter ending March 31, 2022. In the past year ABBV has met analyst expectations once and beat the expectations the other three quarters. Zacks Investment Research reports that the 2022 Price to Earnings ratio for ABBV is 11.15 vs. an industry ratio of 15.60. | AbbVie Inc. (ABBV)is reporting for the quarter ending March 31, 2022. In the past year ABBV has met analyst expectations once and beat the expectations the other three quarters. Zacks Investment Research reports that the 2022 Price to Earnings ratio for ABBV is 11.15 vs. an industry ratio of 15.60. | AbbVie Inc. (ABBV)is reporting for the quarter ending March 31, 2022. In the past year ABBV has met analyst expectations once and beat the expectations the other three quarters. Zacks Investment Research reports that the 2022 Price to Earnings ratio for ABBV is 11.15 vs. an industry ratio of 15.60. | AbbVie Inc. (ABBV)is reporting for the quarter ending March 31, 2022. In the past year ABBV has met analyst expectations once and beat the expectations the other three quarters. Zacks Investment Research reports that the 2022 Price to Earnings ratio for ABBV is 11.15 vs. an industry ratio of 15.60. |
23,432 | 2022-04-28 00:00:00 UTC | Drug/Biotech Stocks Q1 Earnings Due on Apr 29: BMY, ABBV, AZN | ABBV | https://www.nasdaq.com/articles/drug-biotech-stocks-q1-earnings-due-on-apr-29%3A-bmy-abbv-azn | null | null | First-quarter earnings kick-started last week for the pharma/biotech sector. A few pharma bigwigs have reported so far, along with a few biotech players. Several are scheduled to report shortly. Bellwether Johnson & Johnson JNJ reported mixed results, beating on earnings but missing revenue estimates. Swiss major Nova... | Let’s analyze three pharma/biotech companies — Bristol Myers BMY, AbbVie ABBV and AstraZeneca AZN that are set to report results on Apr 29. AbbVie AbbVie has an excellent track record, with earnings beating estimates in all of the last four quarters, the surprise being 2.55%, on average. Per our proven model, AbbVie is... | AbbVie Inc. Price, Consensus and EPS Surprise AbbVie Inc. price-consensus-eps-surprise-chart | AbbVie Inc. Quote Strong demand for immunology drugs, aesthetics and cosmetics products is expected to have driven sales in the first quarter of 2022. Let’s analyze three pharma/biotech companies — Bristol Myers BMY, AbbVie A... | Let’s analyze three pharma/biotech companies — Bristol Myers BMY, AbbVie ABBV and AstraZeneca AZN that are set to report results on Apr 29. AbbVie AbbVie has an excellent track record, with earnings beating estimates in all of the last four quarters, the surprise being 2.55%, on average. Per our proven model, AbbVie is... | Let’s analyze three pharma/biotech companies — Bristol Myers BMY, AbbVie ABBV and AstraZeneca AZN that are set to report results on Apr 29. AbbVie AbbVie has an excellent track record, with earnings beating estimates in all of the last four quarters, the surprise being 2.55%, on average. Per our proven model, AbbVie is... |
23,433 | 2022-04-28 00:00:00 UTC | 7 A-Rated Dividend Stocks to Buy Forever | ABBV | https://www.nasdaq.com/articles/7-a-rated-dividend-stocks-to-buy-forever | null | null | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
Quality dividend stocks like these can see portfolios through good times and bad. Buy these and hold them forever.
AbbVie (ABBV): 3.64% forward yield. The market is overreacting to recent news with this pharmaceutical giant.
Best Buy (BBY): 3.86% forward yi... | AbbVie (ABBV): 3.64% forward yield. That’s the case here with these seven A-rated dividend stocks: ABBV AbbVie $156.27 BBY Best Buy $93.23 CAG ConAgra Brands $35.46 DRI Darden Restaurants $132.07 FNF Fidelity National Financial $39.42 SCCO Southern Copper $61.84 WBA Walgreens Boot Alliance $44.39 AbbVie (ABBV) Source: ... | That’s the case here with these seven A-rated dividend stocks: ABBV AbbVie $156.27 BBY Best Buy $93.23 CAG ConAgra Brands $35.46 DRI Darden Restaurants $132.07 FNF Fidelity National Financial $39.42 SCCO Southern Copper $61.84 WBA Walgreens Boot Alliance $44.39 AbbVie (ABBV) Source: Piotr Swat / Shutterstock.com After ... | That’s the case here with these seven A-rated dividend stocks: ABBV AbbVie $156.27 BBY Best Buy $93.23 CAG ConAgra Brands $35.46 DRI Darden Restaurants $132.07 FNF Fidelity National Financial $39.42 SCCO Southern Copper $61.84 WBA Walgreens Boot Alliance $44.39 AbbVie (ABBV) Source: Piotr Swat / Shutterstock.com After ... | AbbVie (ABBV): 3.64% forward yield. That’s the case here with these seven A-rated dividend stocks: ABBV AbbVie $156.27 BBY Best Buy $93.23 CAG ConAgra Brands $35.46 DRI Darden Restaurants $132.07 FNF Fidelity National Financial $39.42 SCCO Southern Copper $61.84 WBA Walgreens Boot Alliance $44.39 AbbVie (ABBV) Source: ... |
23,434 | 2022-04-28 00:00:00 UTC | Eli Lilly (LLY) Q1 Earnings and Revenues Top Estimates | ABBV | https://www.nasdaq.com/articles/eli-lilly-lly-q1-earnings-and-revenues-top-estimates | null | null | Eli Lilly (LLY) came out with quarterly earnings of $2.62 per share, beating the Zacks Consensus Estimate of $2.32 per share. This compares to earnings of $1.87 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of 12.93%. A quarter ago, it wa... | One other stock from the same industry, AbbVie (ABBV), is yet to report results for the quarter ended March 2022. AbbVie's revenues are expected to be $13.55 billion, up 4.2% from the year-ago quarter. AbbVie Inc. (ABBV): Free Stock Analysis Report | One other stock from the same industry, AbbVie (ABBV), is yet to report results for the quarter ended March 2022. AbbVie's revenues are expected to be $13.55 billion, up 4.2% from the year-ago quarter. AbbVie Inc. (ABBV): Free Stock Analysis Report | One other stock from the same industry, AbbVie (ABBV), is yet to report results for the quarter ended March 2022. AbbVie's revenues are expected to be $13.55 billion, up 4.2% from the year-ago quarter. AbbVie Inc. (ABBV): Free Stock Analysis Report | One other stock from the same industry, AbbVie (ABBV), is yet to report results for the quarter ended March 2022. AbbVie's revenues are expected to be $13.55 billion, up 4.2% from the year-ago quarter. AbbVie Inc. (ABBV): Free Stock Analysis Report |
23,435 | 2022-04-28 00:00:00 UTC | Why Earnings Season Could Be Great for AbbVie (ABBV) | ABBV | https://www.nasdaq.com/articles/why-earnings-season-could-be-great-for-abbvie-abbv | null | null | Investors are always looking for stocks that are poised to beat at earnings season and AbbVie Inc. ABBV may be one such company. The firm has earnings coming up pretty soon, and events are shaping up quite nicely for their report.
That is because AbbVie is seeing favorable earnings estimate revision activity as of lat... | After all, analysts raising estimates right before earnings — with the most up-to-date information possible — is a pretty good indicator of some favorable trends underneath the surface for ABBV in this report. Given that ABBV has a Zacks Rank #3 and an ESP in positive territory, investors might want to consider this st... | This suggests that analysts have very recently bumped up their estimates for ABBV, giving the stock a Zacks Earnings ESP of +0.18% heading into earnings season. Clearly, recent earnings estimate revisions suggest that good things are ahead for AbbVie, and that a beat might be in the cards for the upcoming report. Inves... | This suggests that analysts have very recently bumped up their estimates for ABBV, giving the stock a Zacks Earnings ESP of +0.18% heading into earnings season. Given that ABBV has a Zacks Rank #3 and an ESP in positive territory, investors might want to consider this stock ahead of earnings. Investors are always looki... | Given that ABBV has a Zacks Rank #3 and an ESP in positive territory, investors might want to consider this stock ahead of earnings. Clearly, recent earnings estimate revisions suggest that good things are ahead for AbbVie, and that a beat might be in the cards for the upcoming report. Investors are always looking for ... |
23,436 | 2022-04-27 00:00:00 UTC | 3 Small-Cap Medical Stocks With Big Momentum | ABBV | https://www.nasdaq.com/articles/3-small-cap-medical-stocks-with-big-momentum | null | null | Rengenxbio (NASDAQ: RGNX), Corcept Therapeutics (NASDAQ: CORT), and Pacira BioSciences (NASDAQ: PCRX) are all small-cap healthcare stocks with market caps below $3.5 billion. While the share prices of many companies in this sector have plummeted recently, these three have risen in the past three months.
That said, they... | Most of Regenxbio's 2021 revenue came from a $370 million upfront payment from AbbVie as part of the company's collaboration agreement in developing RGX-314, a one-time gene therapy intended to treat wet, age-related macular degeneration (wet AMD), diabetic retinopathy (DR), and other chronic retinal diseases. The deal... | Most of Regenxbio's 2021 revenue came from a $370 million upfront payment from AbbVie as part of the company's collaboration agreement in developing RGX-314, a one-time gene therapy intended to treat wet, age-related macular degeneration (wet AMD), diabetic retinopathy (DR), and other chronic retinal diseases. The deal... | Most of Regenxbio's 2021 revenue came from a $370 million upfront payment from AbbVie as part of the company's collaboration agreement in developing RGX-314, a one-time gene therapy intended to treat wet, age-related macular degeneration (wet AMD), diabetic retinopathy (DR), and other chronic retinal diseases. The deal... | Most of Regenxbio's 2021 revenue came from a $370 million upfront payment from AbbVie as part of the company's collaboration agreement in developing RGX-314, a one-time gene therapy intended to treat wet, age-related macular degeneration (wet AMD), diabetic retinopathy (DR), and other chronic retinal diseases. The deal... |
23,437 | 2022-04-27 00:00:00 UTC | AbbVie: Health Canada Approves VRAYLAR - Quick Facts | ABBV | https://www.nasdaq.com/articles/abbvie%3A-health-canada-approves-vraylar-quick-facts | null | null | (RTTNews) - AbbVie (ABBV) said Health Canada has approved VRAYLAR (cariprazine) as monotherapy for the acute management of manic, mixed, and depressive episodes associated with bipolar l disorder in adults, and the treatment of schizophrenia in adults. VRAYLAR is a new atypical antipsychotic medication with partial ago... | (RTTNews) - AbbVie (ABBV) said Health Canada has approved VRAYLAR (cariprazine) as monotherapy for the acute management of manic, mixed, and depressive episodes associated with bipolar l disorder in adults, and the treatment of schizophrenia in adults. VRAYLAR is being developed jointly by AbbVie and Gedeon Richter, wi... | (RTTNews) - AbbVie (ABBV) said Health Canada has approved VRAYLAR (cariprazine) as monotherapy for the acute management of manic, mixed, and depressive episodes associated with bipolar l disorder in adults, and the treatment of schizophrenia in adults. VRAYLAR is being developed jointly by AbbVie and Gedeon Richter, wi... | (RTTNews) - AbbVie (ABBV) said Health Canada has approved VRAYLAR (cariprazine) as monotherapy for the acute management of manic, mixed, and depressive episodes associated with bipolar l disorder in adults, and the treatment of schizophrenia in adults. VRAYLAR is being developed jointly by AbbVie and Gedeon Richter, wi... | (RTTNews) - AbbVie (ABBV) said Health Canada has approved VRAYLAR (cariprazine) as monotherapy for the acute management of manic, mixed, and depressive episodes associated with bipolar l disorder in adults, and the treatment of schizophrenia in adults. VRAYLAR is being developed jointly by AbbVie and Gedeon Richter, wi... |
23,438 | 2022-04-27 00:00:00 UTC | Will Biogen (BIIB) Succeed in Beating Q1 Earnings Estimates? | ABBV | https://www.nasdaq.com/articles/will-biogen-biib-succeed-in-beating-q1-earnings-estimates | null | null | We expect Biogen BIIB to beat expectations when it reports first-quarter 2022 results on May 3, before market open. In the last reported quarter, the company delivered an earnings surprise of 2.11%.
The company’s earnings beat estimates in each of the last four quarters. The company has a four-quarter earnings surprise... | Zacks Rank: Biogen has a Zacks Rank #3 Other Stocks to Consider Here are some large drug/biotech stocks that also have the right combination of elements to beat on earnings this time around: AbbVie ABBV with an Earnings ESP of +0.18% and a Zacks Rank #3. AbbVie’s stock has surged 17.6% this year so far. AbbVie topped e... | Zacks Rank: Biogen has a Zacks Rank #3 Other Stocks to Consider Here are some large drug/biotech stocks that also have the right combination of elements to beat on earnings this time around: AbbVie ABBV with an Earnings ESP of +0.18% and a Zacks Rank #3. AbbVie’s stock has surged 17.6% this year so far. AbbVie topped e... | Zacks Rank: Biogen has a Zacks Rank #3 Other Stocks to Consider Here are some large drug/biotech stocks that also have the right combination of elements to beat on earnings this time around: AbbVie ABBV with an Earnings ESP of +0.18% and a Zacks Rank #3. AbbVie’s stock has surged 17.6% this year so far. AbbVie topped e... | AbbVie topped earnings estimates in three of the last four quarters. Zacks Rank: Biogen has a Zacks Rank #3 Other Stocks to Consider Here are some large drug/biotech stocks that also have the right combination of elements to beat on earnings this time around: AbbVie ABBV with an Earnings ESP of +0.18% and a Zacks Rank ... |
23,439 | 2022-04-26 00:00:00 UTC | AbbVie: What to Expect from Q1 Earnings | ABBV | https://www.nasdaq.com/articles/abbvie%3A-what-to-expect-from-q1-earnings | null | null | Shares of biopharma company AbbVie (NYSE: ABBV) have surged 15.5% year-to-date, outperforming the broader market. Amid the volatility, many investors prefer safer bets like AbbVie, which offers an attractive dividend yield.
AbbVie’s dividend yield stands at 3.49%, ahead of the healthcare sector’s average dividend yield... | Wall Street’s Take Ahead of the print, BMO Capital analyst Gary Nachman reiterated a Buy rating on AbbVie and raised the price target to $174 from $161 based on an improving outlook. Specifically, the analyst is optimistic about “immunology with impressive Skyrizi Rx trends and Rinvoq growth taking JAK share (recent po... | Specifically, the analyst is optimistic about “immunology with impressive Skyrizi Rx trends and Rinvoq growth taking JAK share (recent positive physician feedback on increasing use), and Neuroscience led by robust migraine franchise accelerating with Qulipta/Ubrelvy taking share (also positive physician feedback).” Fur... | AbbVie is widely known for its blockbuster autoimmune disease drug Humira, which generated $20.7 billion in revenue in 2021, accounting for 37% of the company’s overall revenue. Specifically, the analyst is optimistic about “immunology with impressive Skyrizi Rx trends and Rinvoq growth taking JAK share (recent positiv... | Wall Street’s Take Ahead of the print, BMO Capital analyst Gary Nachman reiterated a Buy rating on AbbVie and raised the price target to $174 from $161 based on an improving outlook. Shares of biopharma company AbbVie (NYSE: ABBV) have surged 15.5% year-to-date, outperforming the broader market. Amid the volatility, ma... |
23,440 | 2022-04-26 00:00:00 UTC | Universal Health (UHS) Q1 Earnings Miss Mark, Tumble Y/Y | ABBV | https://www.nasdaq.com/articles/universal-health-uhs-q1-earnings-miss-mark-tumble-y-y | null | null | Universal Health Services, Inc. UHS reported first-quarter 2022 adjusted earnings of $2.15 per share, which missed the Zacks Consensus Estimate of $2.47 by 13%. The bottom line decreased 11.9% year over year.
Results were hurt by escalating expenses and lower admissions in its Behavioral Health Care Services segment. ... | AbbVie Inc. ABBV became one of the top-most pharma companies after acquiring Botox maker Allergan in a cash-and-stock deal for $63 billion in May 2020. ABBV is currently Zacks #3 Ranked and has an Earnings ESP of +0.18%. ABBV will report first-quarter earnings results on Apr 29. | AbbVie Inc. ABBV became one of the top-most pharma companies after acquiring Botox maker Allergan in a cash-and-stock deal for $63 billion in May 2020. ABBV is currently Zacks #3 Ranked and has an Earnings ESP of +0.18%. ABBV will report first-quarter earnings results on Apr 29. | AbbVie Inc. ABBV became one of the top-most pharma companies after acquiring Botox maker Allergan in a cash-and-stock deal for $63 billion in May 2020. ABBV is currently Zacks #3 Ranked and has an Earnings ESP of +0.18%. ABBV will report first-quarter earnings results on Apr 29. | AbbVie Inc. ABBV became one of the top-most pharma companies after acquiring Botox maker Allergan in a cash-and-stock deal for $63 billion in May 2020. ABBV is currently Zacks #3 Ranked and has an Earnings ESP of +0.18%. ABBV will report first-quarter earnings results on Apr 29. |
23,441 | 2022-04-26 00:00:00 UTC | Healthcare ETFs in Focus Ahead of Q1 Earnings | ABBV | https://www.nasdaq.com/articles/healthcare-etfs-in-focus-ahead-of-q1-earnings | null | null | The healthcare sector has gained some momentum lately on investors’ rush to safety in a volatile stock market. The sector is non-cyclical in nature, which in turn, is providing a cushion to the portfolio. Additionally, lockdown measures in China have led to global growth concerns, thereby raising the appeal for defensi... | The further price movement of these funds depends on earnings releases from some big names like Pfizer PFE, Merck MRK, Amgen AMGN, AbbVie ABBV and Gilead Sciences GILD that dominate returns. AbbVie has a Zacks Rank #3 and an Earnings ESP of +0.18%. AbbVie Inc. (ABBV): Free Stock Analysis Report | The further price movement of these funds depends on earnings releases from some big names like Pfizer PFE, Merck MRK, Amgen AMGN, AbbVie ABBV and Gilead Sciences GILD that dominate returns. AbbVie has a Zacks Rank #3 and an Earnings ESP of +0.18%. AbbVie Inc. (ABBV): Free Stock Analysis Report | The further price movement of these funds depends on earnings releases from some big names like Pfizer PFE, Merck MRK, Amgen AMGN, AbbVie ABBV and Gilead Sciences GILD that dominate returns. AbbVie has a Zacks Rank #3 and an Earnings ESP of +0.18%. AbbVie Inc. (ABBV): Free Stock Analysis Report | The further price movement of these funds depends on earnings releases from some big names like Pfizer PFE, Merck MRK, Amgen AMGN, AbbVie ABBV and Gilead Sciences GILD that dominate returns. AbbVie has a Zacks Rank #3 and an Earnings ESP of +0.18%. AbbVie Inc. (ABBV): Free Stock Analysis Report |
23,442 | 2022-04-26 00:00:00 UTC | Walgreens, drugmakers blame others for San Francisco's opioid crisis | ABBV | https://www.nasdaq.com/articles/walgreens-drugmakers-blame-others-for-san-franciscos-opioid-crisis | null | null | By Dietrich Knauth
April 26 (Reuters) - Pharmacy chain Walgreens Boots Alliance WBA.O and other defendants on Tuesday said they were not to blame for the opioid crisis in San Francisco, and that they acted responsibly when providing legal medications to patients in pain.
"Almost all of those prescriptions were written ... | San Francisco has accused Walgreens, Teva Pharmaceutical Industries Ltd TEVA.TA, AbbVie Inc's ABBV.N Allergan unit, and drug distributor Anda Inc, which is owned by Teva, of creating a "public nuisance" by flooding the city with prescription opioids and failing to prevent the drugs from being diverted for illegal use. ... | San Francisco has accused Walgreens, Teva Pharmaceutical Industries Ltd TEVA.TA, AbbVie Inc's ABBV.N Allergan unit, and drug distributor Anda Inc, which is owned by Teva, of creating a "public nuisance" by flooding the city with prescription opioids and failing to prevent the drugs from being diverted for illegal use. ... | San Francisco has accused Walgreens, Teva Pharmaceutical Industries Ltd TEVA.TA, AbbVie Inc's ABBV.N Allergan unit, and drug distributor Anda Inc, which is owned by Teva, of creating a "public nuisance" by flooding the city with prescription opioids and failing to prevent the drugs from being diverted for illegal use. ... | San Francisco has accused Walgreens, Teva Pharmaceutical Industries Ltd TEVA.TA, AbbVie Inc's ABBV.N Allergan unit, and drug distributor Anda Inc, which is owned by Teva, of creating a "public nuisance" by flooding the city with prescription opioids and failing to prevent the drugs from being diverted for illegal use. ... |
23,443 | 2022-04-26 00:00:00 UTC | 3 Dividend Stocks for Value Investors Seeking Regular Income | ABBV | https://www.nasdaq.com/articles/3-dividend-stocks-for-value-investors-seeking-regular-income | null | null | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
3M Company (MMM): This dividend stock has been paying dividends to its shareholders for more than 100 years.
AbbVie (ABBV): AbbVie has doubled its dividend over a span of seven years, after its spin-off from Abbot Laboratories.
Johnson & Johnson (JNJ): The... | AbbVie (ABBV): AbbVie has doubled its dividend over a span of seven years, after its spin-off from Abbot Laboratories. MMM 3M Company $146.73 ABBV AbbVie $154.25 JNJ Johnson & Johnson $183.88 3M Company (MMM) Source: Ken Wolter / Shutterstock.com 3M Company (NYSE:MMM) has paid dividends to its shareholders without int... | MMM 3M Company $146.73 ABBV AbbVie $154.25 JNJ Johnson & Johnson $183.88 3M Company (MMM) Source: Ken Wolter / Shutterstock.com 3M Company (NYSE:MMM) has paid dividends to its shareholders without interruption for more than 100 years. AbbVie (ABBV): AbbVie has doubled its dividend over a span of seven years, after its ... | MMM 3M Company $146.73 ABBV AbbVie $154.25 JNJ Johnson & Johnson $183.88 3M Company (MMM) Source: Ken Wolter / Shutterstock.com 3M Company (NYSE:MMM) has paid dividends to its shareholders without interruption for more than 100 years. AbbVie (ABBV): AbbVie has doubled its dividend over a span of seven years, after its ... | AbbVie (ABBV): AbbVie has doubled its dividend over a span of seven years, after its spin-off from Abbot Laboratories. MMM 3M Company $146.73 ABBV AbbVie $154.25 JNJ Johnson & Johnson $183.88 3M Company (MMM) Source: Ken Wolter / Shutterstock.com 3M Company (NYSE:MMM) has paid dividends to its shareholders without int... |
23,444 | 2022-04-26 00:00:00 UTC | 7 Retirement Stocks to Buy to Sleep Soundly at Night | ABBV | https://www.nasdaq.com/articles/7-retirement-stocks-to-buy-to-sleep-soundly-at-night | null | null | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
Kimberly Clark Corp (KMB) Kimberly-Clark produces many types of products, including diapers and feminine hygiene products. The company has delivered 50 consecutive years of dividend increases.
Lockheed Martin (LMT) Lockheed Martin is a company that has been... | AbbVie (ABBV) Humira is about to go off-patent. Ticker Company Current Price KMB Kimberly Clark Corp $143.48 LMT Lockheed Martin Corporation $442.89 MRK Merck & Co. $85.44 ABBV AbbVie $156.30 DLR Digital Realty Trust, Inc. $151.56 GIS General Mills, Inc. $72.20 PG Procter & Gamble Co $162.55 Retirement Stocks: Kimberly... | Ticker Company Current Price KMB Kimberly Clark Corp $143.48 LMT Lockheed Martin Corporation $442.89 MRK Merck & Co. $85.44 ABBV AbbVie $156.30 DLR Digital Realty Trust, Inc. $151.56 GIS General Mills, Inc. $72.20 PG Procter & Gamble Co $162.55 Retirement Stocks: Kimberly Clark (KMB) Source: Trong Nguyen / Shutterstock... | Ticker Company Current Price KMB Kimberly Clark Corp $143.48 LMT Lockheed Martin Corporation $442.89 MRK Merck & Co. $85.44 ABBV AbbVie $156.30 DLR Digital Realty Trust, Inc. $151.56 GIS General Mills, Inc. $72.20 PG Procter & Gamble Co $162.55 Retirement Stocks: Kimberly Clark (KMB) Source: Trong Nguyen / Shutterstock... | Ticker Company Current Price KMB Kimberly Clark Corp $143.48 LMT Lockheed Martin Corporation $442.89 MRK Merck & Co. $85.44 ABBV AbbVie $156.30 DLR Digital Realty Trust, Inc. $151.56 GIS General Mills, Inc. $72.20 PG Procter & Gamble Co $162.55 Retirement Stocks: Kimberly Clark (KMB) Source: Trong Nguyen / Shutterstock... |
23,445 | 2022-04-26 00:00:00 UTC | What Stocks to Buy That Should Do Well in a Recession — Our 7 Top Picks | ABBV | https://www.nasdaq.com/articles/what-stocks-to-buy-that-should-do-well-in-a-recession-our-7-top-picks | null | null | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
McDonald’s Corp (NYSE:MCD) — People eat fast food in a recession; pays a 2.21% yield with good dividend growth
Target (NYSE:TGT) — a growing retailer with good cash flow; pays a stable dividend with a 1.49% yield
Walmart (NYSE:WMT) — A discount retailer att... | InvestorPlace - Stock Market News, Stock Advice & Trading Tips McDonald’s Corp (NYSE:MCD) — People eat fast food in a recession; pays a 2.21% yield with good dividend growth Target (NYSE:TGT) — a growing retailer with good cash flow; pays a stable dividend with a 1.49% yield Walmart (NYSE:WMT) — A discount retailer att... | InvestorPlace - Stock Market News, Stock Advice & Trading Tips McDonald’s Corp (NYSE:MCD) — People eat fast food in a recession; pays a 2.21% yield with good dividend growth Target (NYSE:TGT) — a growing retailer with good cash flow; pays a stable dividend with a 1.49% yield Walmart (NYSE:WMT) — A discount retailer att... | InvestorPlace - Stock Market News, Stock Advice & Trading Tips McDonald’s Corp (NYSE:MCD) — People eat fast food in a recession; pays a 2.21% yield with good dividend growth Target (NYSE:TGT) — a growing retailer with good cash flow; pays a stable dividend with a 1.49% yield Walmart (NYSE:WMT) — A discount retailer att... | InvestorPlace - Stock Market News, Stock Advice & Trading Tips McDonald’s Corp (NYSE:MCD) — People eat fast food in a recession; pays a 2.21% yield with good dividend growth Target (NYSE:TGT) — a growing retailer with good cash flow; pays a stable dividend with a 1.49% yield Walmart (NYSE:WMT) — A discount retailer att... |
23,446 | 2022-04-26 00:00:00 UTC | Will Merck (MRK) Beat Expectations This Earnings Season? | ABBV | https://www.nasdaq.com/articles/will-merck-mrk-beat-expectations-this-earnings-season | null | null | We expect Merck MRK to beat expectations when it reports first-quarter 2022 results on Apr 28 before market open. In the last reported quarter, the company delivered an earnings surprise of 23.29%.
The large drugmaker’s performance has been mixed, with the company missing earnings expectations in two of the trailing fo... | Zacks Rank: Merck has a Zacks Rank #3 Other Stocks to Consider Here are some large drug stocks that also have the right combination of elements to beat on earnings this time around: AbbVie ABBV with an Earnings ESP of +0.18% and a Zacks Rank #3. AbbVie’s stock has rallied 17.7% this year so far. AbbVie topped earnings ... | Zacks Rank: Merck has a Zacks Rank #3 Other Stocks to Consider Here are some large drug stocks that also have the right combination of elements to beat on earnings this time around: AbbVie ABBV with an Earnings ESP of +0.18% and a Zacks Rank #3. AbbVie’s stock has rallied 17.7% this year so far. AbbVie topped earnings ... | Zacks Rank: Merck has a Zacks Rank #3 Other Stocks to Consider Here are some large drug stocks that also have the right combination of elements to beat on earnings this time around: AbbVie ABBV with an Earnings ESP of +0.18% and a Zacks Rank #3. AbbVie’s stock has rallied 17.7% this year so far. AbbVie topped earnings ... | AbbVie topped earnings estimates in three of the last four quarters. Zacks Rank: Merck has a Zacks Rank #3 Other Stocks to Consider Here are some large drug stocks that also have the right combination of elements to beat on earnings this time around: AbbVie ABBV with an Earnings ESP of +0.18% and a Zacks Rank #3. AbbVi... |
23,447 | 2022-04-25 00:00:00 UTC | AbbVie (ABBV) Outpaces Stock Market Gains: What You Should Know | ABBV | https://www.nasdaq.com/articles/abbvie-abbv-outpaces-stock-market-gains%3A-what-you-should-know-1 | null | null | In the latest trading session, AbbVie (ABBV) closed at $156.30, marking a +0.85% move from the previous day. This move outpaced the S&P 500's daily gain of 0.57%. Elsewhere, the Dow gained 0.7%, while the tech-heavy Nasdaq lost 0.1%.
Heading into today, shares of the drugmaker had lost 3.93% over the past month, laggin... | In the latest trading session, AbbVie (ABBV) closed at $156.30, marking a +0.85% move from the previous day. Wall Street will be looking for positivity from AbbVie as it approaches its next earnings report date. On that day, AbbVie is projected to report earnings of $3.15 per share, which would represent year-over-year... | In the latest trading session, AbbVie (ABBV) closed at $156.30, marking a +0.85% move from the previous day. Wall Street will be looking for positivity from AbbVie as it approaches its next earnings report date. On that day, AbbVie is projected to report earnings of $3.15 per share, which would represent year-over-year... | In the latest trading session, AbbVie (ABBV) closed at $156.30, marking a +0.85% move from the previous day. Wall Street will be looking for positivity from AbbVie as it approaches its next earnings report date. On that day, AbbVie is projected to report earnings of $3.15 per share, which would represent year-over-year... | In the latest trading session, AbbVie (ABBV) closed at $156.30, marking a +0.85% move from the previous day. On that day, AbbVie is projected to report earnings of $3.15 per share, which would represent year-over-year growth of 6.78%. Wall Street will be looking for positivity from AbbVie as it approaches its next earn... |
23,448 | 2022-04-25 00:00:00 UTC | Walgreens, Teva accused of fueling opioid addiction in quest for new markets | ABBV | https://www.nasdaq.com/articles/walgreens-teva-accused-of-fueling-opioid-addiction-in-quest-for-new-markets | null | null | By Dietrich Knauth
April 25 (Reuters) - Walgreens Boots Alliance WBA.O and Teva Pharmaceutical Industries Ltd TEVA.TA ignored the health risks when they created new markets for opioids, a lawyer for the city of San Francisco told a judge on Monday during opening statements of the first trial to target manufacturers, di... | San Francisco has said that pharmacy chain Walgreens, drugmakers Teva Pharmaceutical Industries Ltd TEVA.TA and AbbVie Inc's ABBV.N Allergan unit, and drug distributor Anda Inc, which is owned by Teva, created a "public nuisance" by flooding the city with prescription opioids and failing to prevent the drugs from being... | San Francisco has said that pharmacy chain Walgreens, drugmakers Teva Pharmaceutical Industries Ltd TEVA.TA and AbbVie Inc's ABBV.N Allergan unit, and drug distributor Anda Inc, which is owned by Teva, created a "public nuisance" by flooding the city with prescription opioids and failing to prevent the drugs from being... | San Francisco has said that pharmacy chain Walgreens, drugmakers Teva Pharmaceutical Industries Ltd TEVA.TA and AbbVie Inc's ABBV.N Allergan unit, and drug distributor Anda Inc, which is owned by Teva, created a "public nuisance" by flooding the city with prescription opioids and failing to prevent the drugs from being... | San Francisco has said that pharmacy chain Walgreens, drugmakers Teva Pharmaceutical Industries Ltd TEVA.TA and AbbVie Inc's ABBV.N Allergan unit, and drug distributor Anda Inc, which is owned by Teva, created a "public nuisance" by flooding the city with prescription opioids and failing to prevent the drugs from being... |
23,449 | 2022-04-25 00:00:00 UTC | Walgreens, Teva face San Francisco trial over opioid epidemic | ABBV | https://www.nasdaq.com/articles/walgreens-teva-face-san-francisco-trial-over-opioid-epidemic | null | null | By Dietrich Knauth
April 25 (Reuters) - San Francisco will square off on Monday against Walgreens Boots Alliance WBA.O and three other companies accused of fueling an opioid crisis in the city, the first trial to target manufacturers, distributors and pharmacies over the addictive pain medicines.
San Francisco has alle... | San Francisco has alleged that pharmacy chain Walgreens, drugmakers Teva Pharmaceutical Industries Ltd TEVA.TA and AbbVie Inc's ABBV.N Allergan unit, and drug distributor Anda Inc, which is owned by Teva, created a "public nuisance" by flooding the city with prescription opioids and failing to prevent the drugs from be... | San Francisco has alleged that pharmacy chain Walgreens, drugmakers Teva Pharmaceutical Industries Ltd TEVA.TA and AbbVie Inc's ABBV.N Allergan unit, and drug distributor Anda Inc, which is owned by Teva, created a "public nuisance" by flooding the city with prescription opioids and failing to prevent the drugs from be... | San Francisco has alleged that pharmacy chain Walgreens, drugmakers Teva Pharmaceutical Industries Ltd TEVA.TA and AbbVie Inc's ABBV.N Allergan unit, and drug distributor Anda Inc, which is owned by Teva, created a "public nuisance" by flooding the city with prescription opioids and failing to prevent the drugs from be... | San Francisco has alleged that pharmacy chain Walgreens, drugmakers Teva Pharmaceutical Industries Ltd TEVA.TA and AbbVie Inc's ABBV.N Allergan unit, and drug distributor Anda Inc, which is owned by Teva, created a "public nuisance" by flooding the city with prescription opioids and failing to prevent the drugs from be... |
23,450 | 2022-04-24 00:00:00 UTC | These Dividend Stocks Are Trouncing the Market -- Are They Still Buys? | ABBV | https://www.nasdaq.com/articles/these-dividend-stocks-are-trouncing-the-market-are-they-still-buys | null | null | Stocks are always going up. It's just not all of them that do so. But there are always outliers that rise even when the overall market is sinking.
With growth stocks out of favor, many investors have turned to big drugmakers and energy giants that pay attractive dividends. Here are three such dividend stocks that are t... | Some could also be shaking off earlier concerns that AbbVie won't be able to offset anticipated sales declines for Humira when it loses U.S. exclusivity next year. AbbVie The S&P 500 index is down 10% year to date. Meanwhile, shares of AbbVie (NYSE: ABBV) have jumped 14%. | AbbVie's dividend yield of over 3.6% continues to attract investors. AbbVie The S&P 500 index is down 10% year to date. Meanwhile, shares of AbbVie (NYSE: ABBV) have jumped 14%. | See the 10 stocks *Stock Advisor returns as of April 7, 2022 Keith Speights owns AbbVie. AbbVie The S&P 500 index is down 10% year to date. Meanwhile, shares of AbbVie (NYSE: ABBV) have jumped 14%. | AbbVie The S&P 500 index is down 10% year to date. Meanwhile, shares of AbbVie (NYSE: ABBV) have jumped 14%. AbbVie's dividend yield of over 3.6% continues to attract investors. |
23,451 | 2022-04-24 00:00:00 UTC | 3 Dividend Growth Titans to Increase Your Passive Income | ABBV | https://www.nasdaq.com/articles/3-dividend-growth-titans-to-increase-your-passive-income | null | null | At a time when inflation is skyrocketing, it's particularly hard for many people's salaries to keep up with their most basic costs. A great alternative approach to cover those costs, without having to work more or wait on tough-to-get raises, is to build a passive income stream through dividends.
With that in mind, we ... | Get started now Whether or not you believe McDonald's, AbbVie, or Genuine Parts deserves a spot in your portfolio, a strong and growing passive income stream can be a great tool to have as you try to fight inflation. They came up with McDonald's (NYSE: MCD), AbbVie (NYSE: ABBV), and Genuine Parts (NYSE: GPC). A healthy... | They came up with McDonald's (NYSE: MCD), AbbVie (NYSE: ABBV), and Genuine Parts (NYSE: GPC). Get started now Whether or not you believe McDonald's, AbbVie, or Genuine Parts deserves a spot in your portfolio, a strong and growing passive income stream can be a great tool to have as you try to fight inflation. A healthy... | They came up with McDonald's (NYSE: MCD), AbbVie (NYSE: ABBV), and Genuine Parts (NYSE: GPC). A healthy addition to any portfolio Eric Volkman (AbbVie): The pharmaceutical sector is not loaded with high-yield dividend payers. One of the best of these is longtime industry veteran AbbVie. | They came up with McDonald's (NYSE: MCD), AbbVie (NYSE: ABBV), and Genuine Parts (NYSE: GPC). A healthy addition to any portfolio Eric Volkman (AbbVie): The pharmaceutical sector is not loaded with high-yield dividend payers. One of the best of these is longtime industry veteran AbbVie. |
23,452 | 2022-04-23 00:00:00 UTC | 3 Dividend Stocks You Can Buy and Hold for Decades | ABBV | https://www.nasdaq.com/articles/3-dividend-stocks-you-can-buy-and-hold-for-decades | null | null | Investors make the most money when they have more of a crockpot mentality than a microwave mentality. Buying and holding for the long term works -- when you pick the right stocks, of course.
We asked three Motley Fool contributors to identify dividend stocks that you can buy and hold for decades. Here's why they chose ... | Over time, Rinvoq, Skyrizi, and other current blockbusters in AbbVie's portfolio will follow in Humira's footsteps with their own LOEs. Here's why they chose AbbVie (NYSE: ABBV), Bristol Myers Squibb (NYSE: BMY), and Eli Lilly (NYSE: LLY). Dividend royalty Keith Speights (AbbVie): Fewer than 40 stocks can claim the sta... | Here's why they chose AbbVie (NYSE: ABBV), Bristol Myers Squibb (NYSE: BMY), and Eli Lilly (NYSE: LLY). Keith Speights owns AbbVie and Bristol Myers Squibb. Dividend royalty Keith Speights (AbbVie): Fewer than 40 stocks can claim the status of Dividend King, the elite group of companies that have increased their divide... | Dividend royalty Keith Speights (AbbVie): Fewer than 40 stocks can claim the status of Dividend King, the elite group of companies that have increased their dividends for 50 years or more. Here's why they chose AbbVie (NYSE: ABBV), Bristol Myers Squibb (NYSE: BMY), and Eli Lilly (NYSE: LLY). AbbVie is one of only three... | Here's why they chose AbbVie (NYSE: ABBV), Bristol Myers Squibb (NYSE: BMY), and Eli Lilly (NYSE: LLY). Dividend royalty Keith Speights (AbbVie): Fewer than 40 stocks can claim the status of Dividend King, the elite group of companies that have increased their dividends for 50 years or more. AbbVie is one of only three... |
23,453 | 2022-04-22 00:00:00 UTC | AbbVie (ABBV) Earnings Expected to Grow: What to Know Ahead of Next Week's Release | ABBV | https://www.nasdaq.com/articles/abbvie-abbv-earnings-expected-to-grow%3A-what-to-know-ahead-of-next-weeks-release | null | null | Wall Street expects a year-over-year increase in earnings on higher revenues when AbbVie (ABBV) reports results for the quarter ended March 2022. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the act... | Wall Street expects a year-over-year increase in earnings on higher revenues when AbbVie (ABBV) reports results for the quarter ended March 2022. How Have the Numbers Shaped Up for AbbVie? For AbbVie, the Most Accurate Estimate is lower than the Zacks Consensus Estimate, suggesting that analysts have recently become be... | Wall Street expects a year-over-year increase in earnings on higher revenues when AbbVie (ABBV) reports results for the quarter ended March 2022. How Have the Numbers Shaped Up for AbbVie? For AbbVie, the Most Accurate Estimate is lower than the Zacks Consensus Estimate, suggesting that analysts have recently become be... | Wall Street expects a year-over-year increase in earnings on higher revenues when AbbVie (ABBV) reports results for the quarter ended March 2022. How Have the Numbers Shaped Up for AbbVie? For AbbVie, the Most Accurate Estimate is lower than the Zacks Consensus Estimate, suggesting that analysts have recently become be... | For the last reported quarter, it was expected that AbbVie would post earnings of $3.29 per share when it actually produced earnings of $3.31, delivering a surprise of +0.61%. Wall Street expects a year-over-year increase in earnings on higher revenues when AbbVie (ABBV) reports results for the quarter ended March 2022... |
23,454 | 2022-04-22 00:00:00 UTC | iShares Core High Dividend ETF Experiences Big Inflow | ABBV | https://www.nasdaq.com/articles/ishares-core-high-dividend-etf-experiences-big-inflow | null | null | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares Core High Dividend ETF (Symbol: HDV) where we have detected an approximate $792.0 million dollar inflow -- that's a 8.5% increase week over week in outstanding units (from 85,550,000... | Among the largest underlying components of HDV, in trading today AbbVie Inc (Symbol: ABBV) is off about 1.3%, Johnson & Johnson (Symbol: JNJ) is down about 0.8%, and Verizon Communications Inc (Symbol: VZ) is lower by about 5.3%. For a complete list of holdings, visit the HDV Holdings page » The chart below shows the o... | Among the largest underlying components of HDV, in trading today AbbVie Inc (Symbol: ABBV) is off about 1.3%, Johnson & Johnson (Symbol: JNJ) is down about 0.8%, and Verizon Communications Inc (Symbol: VZ) is lower by about 5.3%. For a complete list of holdings, visit the HDV Holdings page » The chart below shows the o... | Among the largest underlying components of HDV, in trading today AbbVie Inc (Symbol: ABBV) is off about 1.3%, Johnson & Johnson (Symbol: JNJ) is down about 0.8%, and Verizon Communications Inc (Symbol: VZ) is lower by about 5.3%. Looking today at week-over-week shares outstanding changes among the universe of ETFs cove... | Among the largest underlying components of HDV, in trading today AbbVie Inc (Symbol: ABBV) is off about 1.3%, Johnson & Johnson (Symbol: JNJ) is down about 0.8%, and Verizon Communications Inc (Symbol: VZ) is lower by about 5.3%. Looking today at week-over-week shares outstanding changes among the universe of ETFs cove... |
23,455 | 2022-04-22 00:00:00 UTC | See Which Of The Latest 13F Filers Holds AbbVie | ABBV | https://www.nasdaq.com/articles/see-which-of-the-latest-13f-filers-holds-abbvie-0 | null | null | At Holdings Channel, we have reviewed the latest batch of the 21 most recent 13F filings for the 03/31/2022 reporting period, and noticed that AbbVie Inc (Symbol: ABBV) was held by 14 of these funds. When hedge fund managers appear to be thinking alike, we find it is a good idea to take a closer look.
Before we proceed... | At Holdings Channel, we have reviewed the latest batch of the 21 most recent 13F filings for the 03/31/2022 reporting period, and noticed that AbbVie Inc (Symbol: ABBV) was held by 14 of these funds. While looking at individual 13F filings can sometimes be misleading due to the long-only nature of the information, the ... | At Holdings Channel, we have reviewed the latest batch of the 21 most recent 13F filings for the 03/31/2022 reporting period, and noticed that AbbVie Inc (Symbol: ABBV) was held by 14 of these funds. Gateway Investment Advisers LLC 524,793 4-10 Find out the full Top 10 Hedge Funds Holding ABBV » We'll keep following th... | We then compared that number to the sum total of ABBV shares those same funds held back at the 12/31/2021 period, to see how the aggregate share count held by hedge funds has moved for ABBV. Gateway Investment Advisers LLC 524,793 4-10 Find out the full Top 10 Hedge Funds Holding ABBV » We'll keep following the latest ... | Existing +144 +$67 Aggregate Change: -3,638 +$17,566 In terms of shares owned, we count 5 of the above funds having increased existing ABBV positions from 12/31/2021 to 03/31/2022, with 6 having decreased their positions and 1 new position. Gateway Investment Advisers LLC 524,793 4-10 Find out the full Top 10 Hedge Fun... |
23,456 | 2022-04-22 00:00:00 UTC | Pre-Market Most Active for Apr 22, 2022 : TQQQ, SQQQ, TWTR, QQQ, CRXT, RDBX, SNAP, CLF, AAPL, ABBV, NIO, GPS | ABBV | https://www.nasdaq.com/articles/pre-market-most-active-for-apr-22-2022-%3A-tqqq-sqqq-twtr-qqq-crxt-rdbx-snap-clf-aapl-abbv | null | null | The NASDAQ 100 Pre-Market Indicator is up 19.03 to 13,739.48. The total Pre-Market volume is currently 16,431,399 shares traded.
The following are the most active stocks for the pre-market session:
ProShares UltraPro QQQ (TQQQ) is +0.44 at $45.53, with 1,816,485 shares traded. This represents a 15.09% increase from i... | AbbVie Inc. (ABBV) is -0.72 at $157.80, with 608,090 shares traded. ABBV is scheduled to provide an earnings report on 4/29/2022, for the fiscal quarter ending Mar2022. Twitter, Inc. (TWTR) is +0.48 at $47.56, with 1,387,528 shares traded.TWTR is scheduled to provide an earnings report on 4/28/2022, for the fiscal quar... | AbbVie Inc. (ABBV) is -0.72 at $157.80, with 608,090 shares traded. ABBV is scheduled to provide an earnings report on 4/29/2022, for the fiscal quarter ending Mar2022. The consensus earnings per share forecast is -0.19 per share, which represents a 6 percent increase over the EPS one Year Ago | AbbVie Inc. (ABBV) is -0.72 at $157.80, with 608,090 shares traded. ABBV is scheduled to provide an earnings report on 4/29/2022, for the fiscal quarter ending Mar2022. The consensus earnings per share forecast is -0.19 per share, which represents a 6 percent increase over the EPS one Year Ago | AbbVie Inc. (ABBV) is -0.72 at $157.80, with 608,090 shares traded. ABBV is scheduled to provide an earnings report on 4/29/2022, for the fiscal quarter ending Mar2022. The NASDAQ 100 Pre-Market Indicator is up 19.03 to 13,739.48. |
23,457 | 2022-04-21 00:00:00 UTC | Notable Thursday Option Activity: HEAR, ADT, ABBV | ABBV | https://www.nasdaq.com/articles/notable-thursday-option-activity%3A-hear-adt-abbv | null | null | Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Turtle Beach Corp (Symbol: HEAR), where a total volume of 1,811 contracts has been traded thus far today, a contract volume which is representative of approximately 181,100 underlying shares (given that... | Especially high volume was seen for the $160 strike call option expiring April 22, 2022, with 7,815 contracts trading so far today, representing approximately 781,500 underlying shares of ABBV. Below is a chart showing ADT's trailing twelve month trading history, with the $5 strike highlighted in orange: And AbbVie Inc... | That number of contracts represents approximately 3.3 million underlying shares, working out to a sizeable 43.7% of ABBV's average daily trading volume over the past month, of 7.6 million shares. Below is a chart showing ADT's trailing twelve month trading history, with the $5 strike highlighted in orange: And AbbVie I... | That number of contracts represents approximately 3.3 million underlying shares, working out to a sizeable 43.7% of ABBV's average daily trading volume over the past month, of 7.6 million shares. Below is a chart showing ADT's trailing twelve month trading history, with the $5 strike highlighted in orange: And AbbVie I... | Especially high volume was seen for the $160 strike call option expiring April 22, 2022, with 7,815 contracts trading so far today, representing approximately 781,500 underlying shares of ABBV. Below is a chart showing ADT's trailing twelve month trading history, with the $5 strike highlighted in orange: And AbbVie Inc... |
23,458 | 2022-04-21 00:00:00 UTC | 2 Charts Big Pharma Investors Need to Understand | ABBV | https://www.nasdaq.com/articles/2-charts-big-pharma-investors-need-to-understand | null | null | For pharma investors to be worth their salt, they need to appreciate the trends that drive the industry. Change tends to be slow, and it's often necessary to hold pharma stocks for years before seeing a significant payoff -- but the winds of change are always blowing, so there's still no time to rest on your laurels.
I... | In contrast, competitors like AbbVie (NYSE: ABBV) and AstraZeneca could see their market shares grow as a result of targeting more lucrative disease areas with their development efforts which are going on today. With money like that, either of the two could even potentially outbid a poorer competitor like AbbVie, which... | In contrast, competitors like AbbVie (NYSE: ABBV) and AstraZeneca could see their market shares grow as a result of targeting more lucrative disease areas with their development efforts which are going on today. With money like that, either of the two could even potentially outbid a poorer competitor like AbbVie, which... | In contrast, competitors like AbbVie (NYSE: ABBV) and AstraZeneca could see their market shares grow as a result of targeting more lucrative disease areas with their development efforts which are going on today. With money like that, either of the two could even potentially outbid a poorer competitor like AbbVie, which... | In contrast, competitors like AbbVie (NYSE: ABBV) and AstraZeneca could see their market shares grow as a result of targeting more lucrative disease areas with their development efforts which are going on today. With money like that, either of the two could even potentially outbid a poorer competitor like AbbVie, which... |
23,459 | 2022-04-21 00:00:00 UTC | Interesting ABBV Put And Call Options For June 3rd | ABBV | https://www.nasdaq.com/articles/interesting-abbv-put-and-call-options-for-june-3rd | null | null | Investors in AbbVie Inc (Symbol: ABBV) saw new options become available today, for the June 3rd expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ABBV options chain for the new June 3rd contracts and identified one put and one call contract of particular interest.
The put contract ... | Of course, a lot of upside could potentially be left on the table if ABBV shares really soar, which is why looking at the trailing twelve month trading history for AbbVie Inc, as well as studying the business fundamentals becomes important. Below is a chart showing ABBV's trailing twelve month trading history, with the... | Below is a chart showing ABBV's trailing twelve month trading history, with the $160.00 strike highlighted in red: Considering the fact that the $160.00 strike represents an approximate 1% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the pos... | Below is a chart showing the trailing twelve month trading history for AbbVie Inc, and highlighting in green where the $150.00 strike is located relative to that history: Turning to the calls side of the option chain, the call contract at the $160.00 strike price has a current bid of $4.65. Below is a chart showing ABB... | At Stock Options Channel, our YieldBoost formula has looked up and down the ABBV options chain for the new June 3rd contracts and identified one put and one call contract of particular interest. Below is a chart showing ABBV's trailing twelve month trading history, with the $160.00 strike highlighted in red: Considerin... |
23,460 | 2022-04-21 00:00:00 UTC | Is Teva Pharmaceuticals a Brilliant Contrarian Pick? | ABBV | https://www.nasdaq.com/articles/is-teva-pharmaceuticals-a-brilliant-contrarian-pick | null | null | The Israeli generic drug giant Teva Pharmaceuticals (NYSE: TEVA) isn't exactly an obvious investment suggestion. Over the last five years, its shares are down by more than 66%, while the broader S&P 500 index's total return has been around 105%. Trouble for Teva: it's barely profitable, its base of revenue may be shrin... | AbbVie, the original developer of Humira, made $20.7 billion from sales of the drug last year. On the other hand, if Teva manages to make a comeback in spite of clear headwinds, it'll bring wealth to the contrarian investors who saw its potential. So far, out-of-court settlements have left Teva on the hook for hundreds... | AbbVie, the original developer of Humira, made $20.7 billion from sales of the drug last year. Teva shareholders have been short on good news over the last five years, with sales, gross profits, FCF, and even total assets shrinking at a dramatic clip. TEVA Normalized Diluted EPS (Quarterly) data by YCharts Within the l... | AbbVie, the original developer of Humira, made $20.7 billion from sales of the drug last year. The Israeli generic drug giant Teva Pharmaceuticals (NYSE: TEVA) isn't exactly an obvious investment suggestion. Why you'd need to be a contrarian to invest in Teva Many investors might shy away from Teva Pharmaceuticals beca... | AbbVie, the original developer of Humira, made $20.7 billion from sales of the drug last year. I think that the contrarian narrative about Teva is largely correct, except when it comes to one critical piece: the potential for shareholder returns. * They just revealed what they believe are the ten best stocks for invest... |
23,461 | 2022-04-20 00:00:00 UTC | Dragonfly Therapeutics Expands Collaboration With AbbVie To Develop Novel Immunotherapies | ABBV | https://www.nasdaq.com/articles/dragonfly-therapeutics-expands-collaboration-with-abbvie-to-develop-novel-immunotherapies | null | null | (RTTNews) - Biotechnology company Dragonfly Therapeutics, Inc. announced Wednesday an expansion of its existing collaboration in oncology and autoimmune disease with peer AbbVie, Inc. (ABBV) to discover and develop Dragonfly's novel immunotherapies for new targets in autoimmune and fibrotic diseases using Dragonfly's p... | (RTTNews) - Biotechnology company Dragonfly Therapeutics, Inc. announced Wednesday an expansion of its existing collaboration in oncology and autoimmune disease with peer AbbVie, Inc. (ABBV) to discover and develop Dragonfly's novel immunotherapies for new targets in autoimmune and fibrotic diseases using Dragonfly's p... | (RTTNews) - Biotechnology company Dragonfly Therapeutics, Inc. announced Wednesday an expansion of its existing collaboration in oncology and autoimmune disease with peer AbbVie, Inc. (ABBV) to discover and develop Dragonfly's novel immunotherapies for new targets in autoimmune and fibrotic diseases using Dragonfly's p... | (RTTNews) - Biotechnology company Dragonfly Therapeutics, Inc. announced Wednesday an expansion of its existing collaboration in oncology and autoimmune disease with peer AbbVie, Inc. (ABBV) to discover and develop Dragonfly's novel immunotherapies for new targets in autoimmune and fibrotic diseases using Dragonfly's p... | (RTTNews) - Biotechnology company Dragonfly Therapeutics, Inc. announced Wednesday an expansion of its existing collaboration in oncology and autoimmune disease with peer AbbVie, Inc. (ABBV) to discover and develop Dragonfly's novel immunotherapies for new targets in autoimmune and fibrotic diseases using Dragonfly's p... |
23,462 | 2022-04-20 00:00:00 UTC | The Best Stocks to Invest $5,000 In Right Now | ABBV | https://www.nasdaq.com/articles/the-best-stocks-to-invest-%245000-in-right-now | null | null | Vaccine stocks have been a big focus over the past couple of years. But there are plenty of other players in the healthcare space that could supercharge your portfolio. They are companies with big revenue growth today -- and even bigger prospects on the horizon. That's why it's a great idea to invest $5,000 in a basket... | AbbVie The bad news for AbbVie (NYSE: ABBV) is that competition for its star immunosuppressive drug Humira is on the horizon. AbbVie expects its two other immunology drugs, Rinvoq and Skyrizi, together to bring in even more revenue than Humira at its peak. And AbbVie's story isn't only about immunology. | AbbVie is set to become the top pharma company by prescription drug market share by 2026, according to Evaluate Pharma. AbbVie The bad news for AbbVie (NYSE: ABBV) is that competition for its star immunosuppressive drug Humira is on the horizon. AbbVie expects its two other immunology drugs, Rinvoq and Skyrizi, togethe... | AbbVie The bad news for AbbVie (NYSE: ABBV) is that competition for its star immunosuppressive drug Humira is on the horizon. AbbVie expects its two other immunology drugs, Rinvoq and Skyrizi, together to bring in even more revenue than Humira at its peak. And AbbVie's story isn't only about immunology. | AbbVie The bad news for AbbVie (NYSE: ABBV) is that competition for its star immunosuppressive drug Humira is on the horizon. AbbVie expects its two other immunology drugs, Rinvoq and Skyrizi, together to bring in even more revenue than Humira at its peak. And AbbVie's story isn't only about immunology. |
23,463 | 2022-04-20 00:00:00 UTC | AbbVie Snags Another Regulatory Approval for This Blockbuster Drug | ABBV | https://www.nasdaq.com/articles/abbvie-snags-another-regulatory-approval-for-this-blockbuster-drug | null | null | On March 16, the Food and Drug Administration (FDA) gave AbbVie's (NYSE: ABBV) Rinvoq the nod to treat adult patients with moderate-to-severe ulcerative colitis who didn't respond to at least one tumor necrosis factor (TNF) blocker.
Why did the FDA approve Rinvoq for its fourth indication? And what could it mean for th... | On March 16, the Food and Drug Administration (FDA) gave AbbVie's (NYSE: ABBV) Rinvoq the nod to treat adult patients with moderate-to-severe ulcerative colitis who didn't respond to at least one tumor necrosis factor (TNF) blocker. And what could it mean for the pharma stock AbbVie? Taking it one step further, 60% to ... | On March 16, the Food and Drug Administration (FDA) gave AbbVie's (NYSE: ABBV) Rinvoq the nod to treat adult patients with moderate-to-severe ulcerative colitis who didn't respond to at least one tumor necrosis factor (TNF) blocker. And what could it mean for the pharma stock AbbVie? Taking it one step further, 60% to ... | On March 16, the Food and Drug Administration (FDA) gave AbbVie's (NYSE: ABBV) Rinvoq the nod to treat adult patients with moderate-to-severe ulcerative colitis who didn't respond to at least one tumor necrosis factor (TNF) blocker. AbbVie's Rinvoq faces competition from the likes of its own Humira and Johnson & Johnso... | On March 16, the Food and Drug Administration (FDA) gave AbbVie's (NYSE: ABBV) Rinvoq the nod to treat adult patients with moderate-to-severe ulcerative colitis who didn't respond to at least one tumor necrosis factor (TNF) blocker. And what could it mean for the pharma stock AbbVie? Taking it one step further, 60% to ... |
23,464 | 2022-04-19 00:00:00 UTC | What to Expect Ahead of HCA Healthcare's (HCA) Q1 Earnings? | ABBV | https://www.nasdaq.com/articles/what-to-expect-ahead-of-hca-healthcares-hca-q1-earnings | null | null | HCA Healthcare, Inc. HCA is scheduled to release first-quarter 2022 results on Apr 22, before the market opens.
In the fourth quarter of 2021, HCA reported adjusted earnings of $4.42 per share, which missed the Zacks Consensus Estimate by 2.9%. However, the bottom line improved 7% year over year on higher revenues.
H... | AbbVie Inc.ABBV has emerged as one of the top-most pharma companies following its acquisition of Botox maker Allergan in a cash-and-stock deal worth $63 billion in May 2020. ABBV has a Zacks Rank #3 and an Earnings ESP of +0.48. ABBV is scheduled to report its first-quarter 2022results on Apr 29. | AbbVie Inc.ABBV has emerged as one of the top-most pharma companies following its acquisition of Botox maker Allergan in a cash-and-stock deal worth $63 billion in May 2020. ABBV has a Zacks Rank #3 and an Earnings ESP of +0.48. ABBV is scheduled to report its first-quarter 2022results on Apr 29. | AbbVie Inc.ABBV has emerged as one of the top-most pharma companies following its acquisition of Botox maker Allergan in a cash-and-stock deal worth $63 billion in May 2020. ABBV has a Zacks Rank #3 and an Earnings ESP of +0.48. ABBV is scheduled to report its first-quarter 2022results on Apr 29. | ABBV has a Zacks Rank #3 and an Earnings ESP of +0.48. AbbVie Inc.ABBV has emerged as one of the top-most pharma companies following its acquisition of Botox maker Allergan in a cash-and-stock deal worth $63 billion in May 2020. ABBV is scheduled to report its first-quarter 2022results on Apr 29. |
23,465 | 2022-04-19 00:00:00 UTC | 3 Things About Abbott Laboratories That Smart Investors Know | ABBV | https://www.nasdaq.com/articles/3-things-about-abbott-laboratories-that-smart-investors-know-0 | null | null | Grace Groner spent 43 years as a secretary at healthcare conglomerate Abbott Laboratories (NYSE: ABT) before retiring and later passing away in 2010 at the age of 100. The fascinating part of her story was that she bought three $60 shares of the company's stock in 1935 (costing a bit over $1,200 in today's dollars) and... | Abbott is dividend royalty Abbott's identity as a company has evolved over the years; it had an enormous pharmaceutical business until it spun off most of it as AbbVie in 2013. Grace Groner spent 43 years as a secretary at healthcare conglomerate Abbott Laboratories (NYSE: ABT) before retiring and later passing away in... | Abbott is dividend royalty Abbott's identity as a company has evolved over the years; it had an enormous pharmaceutical business until it spun off most of it as AbbVie in 2013. Today, the company focuses on nutrition, diagnostics, and medical devices with major shake-ups over the years, including more than $30 billion ... | Abbott is dividend royalty Abbott's identity as a company has evolved over the years; it had an enormous pharmaceutical business until it spun off most of it as AbbVie in 2013. Abbott Labs has paid and raised its dividend for the past 50 consecutive years, making it a Dividend King, an elusive club of just 39 companies... | Abbott is dividend royalty Abbott's identity as a company has evolved over the years; it had an enormous pharmaceutical business until it spun off most of it as AbbVie in 2013. Now, Abbott Labs is a much different company today than it was in 1935 or even 2010 -- but it still has a lot going for it. At the same time, m... |
23,466 | 2022-04-19 00:00:00 UTC | AbbVie: Why It’s an Excellent Recession-Resistant Stock | ABBV | https://www.nasdaq.com/articles/abbvie%3A-why-its-an-excellent-recession-resistant-stock | null | null | AbbVie (ABBV) is trading substantially higher than last year, and I believe that the company will continue to grow throughout the year. ABBV is a leading biotech company that has the potential to generate impressive returns and has near-term upside potential.
This company has a high degree of recession resilience, an o... | Bottom Line AbbVie is projected to grow over the coming years and has several interesting growth strategies that can be capitalized on through synergies. AbbVie (ABBV) is trading substantially higher than last year, and I believe that the company will continue to grow throughout the year. ABBV is a leading biotech comp... | ABBV is a leading biotech company that has the potential to generate impressive returns and has near-term upside potential. For those looking to build a long-term portfolio that captures income, AbbVie is an attractive stock. AbbVie (ABBV) is trading substantially higher than last year, and I believe that the company w... | AbbVie (ABBV) is trading substantially higher than last year, and I believe that the company will continue to grow throughout the year. AbbVie's stock price has hit record highs, which is great for people who own the company's shares. AbbVie is a Premium Dividend Stock AbbVie is one of the best dividend stocks on the N... | AbbVie's stock price has hit record highs, which is great for people who own the company's shares. AbbVie is a Premium Dividend Stock AbbVie is one of the best dividend stocks on the NYSE. AbbVie is a great opportunity for value and income investors despite being at all-time highs. |
23,467 | 2022-04-19 00:00:00 UTC | J&J (JNJ) Beats on Q1 Earnings, Suspends COVID Jab Sales View | ABBV | https://www.nasdaq.com/articles/jj-jnj-beats-on-q1-earnings-suspends-covid-jab-sales-view | null | null | Johnson & Johnson’s JNJ first-quarter 2022 earnings came in at $2.67 per share, which beat the Zacks Consensus Estimate of $2.60. Earnings increased 3.1% from the year-ago period.
Adjusted earnings exclude intangible amortization and some other special items. Including these items, J&J reported first-quarter earnings o... | J&J markets Imbruvica in partnership with AbbVie ABBV. Rising competitive pressure in the United States due to new oral competition has been hurting sales of this AbbVie partnered drug since the past few quarters. AbbVie Inc. (ABBV): Free Stock Analysis Report | J&J markets Imbruvica in partnership with AbbVie ABBV. Rising competitive pressure in the United States due to new oral competition has been hurting sales of this AbbVie partnered drug since the past few quarters. AbbVie Inc. (ABBV): Free Stock Analysis Report | J&J markets Imbruvica in partnership with AbbVie ABBV. Rising competitive pressure in the United States due to new oral competition has been hurting sales of this AbbVie partnered drug since the past few quarters. AbbVie Inc. (ABBV): Free Stock Analysis Report | J&J markets Imbruvica in partnership with AbbVie ABBV. Rising competitive pressure in the United States due to new oral competition has been hurting sales of this AbbVie partnered drug since the past few quarters. AbbVie Inc. (ABBV): Free Stock Analysis Report |
23,468 | 2022-04-19 00:00:00 UTC | AbbVie (ABBV) Stock Sinks As Market Gains: What You Should Know | ABBV | https://www.nasdaq.com/articles/abbvie-abbv-stock-sinks-as-market-gains%3A-what-you-should-know-1 | null | null | AbbVie (ABBV) closed at $156.35 in the latest trading session, marking a -1.89% move from the prior day. This move lagged the S&P 500's daily gain of 1.61%. Meanwhile, the Dow gained 1.45%, and the Nasdaq, a tech-heavy index, added 0.36%.
Prior to today's trading, shares of the drugmaker had lost 0.43% over the past mo... | AbbVie (ABBV) closed at $156.35 in the latest trading session, marking a -1.89% move from the prior day. Investors will be hoping for strength from AbbVie as it approaches its next earnings release, which is expected to be April 29, 2022. On that day, AbbVie is projected to report earnings of $3.15 per share, which wou... | AbbVie (ABBV) closed at $156.35 in the latest trading session, marking a -1.89% move from the prior day. Investors will be hoping for strength from AbbVie as it approaches its next earnings release, which is expected to be April 29, 2022. On that day, AbbVie is projected to report earnings of $3.15 per share, which wou... | AbbVie (ABBV) closed at $156.35 in the latest trading session, marking a -1.89% move from the prior day. Investors will be hoping for strength from AbbVie as it approaches its next earnings release, which is expected to be April 29, 2022. On that day, AbbVie is projected to report earnings of $3.15 per share, which wou... | AbbVie (ABBV) closed at $156.35 in the latest trading session, marking a -1.89% move from the prior day. On that day, AbbVie is projected to report earnings of $3.15 per share, which would represent year-over-year growth of 6.78%. Investors will be hoping for strength from AbbVie as it approaches its next earnings rele... |
23,469 | 2022-04-19 00:00:00 UTC | Is Franklin LibertyQ U.S. Equity ETF (FLQL) a Strong ETF Right Now? | ABBV | https://www.nasdaq.com/articles/is-franklin-libertyq-u.s.-equity-etf-flql-a-strong-etf-right-now-1 | null | null | Designed to provide broad exposure to the Style Box - Large Cap Blend category of the market, the Franklin LibertyQ U.S. Equity ETF (FLQL) is a smart beta exchange traded fund launched on 04/26/2017.
What Are Smart Beta ETFs?
The ETF industry has long been dominated by products based on market cap weighted indexes, a s... | Looking at individual holdings, Abbvie Inc (ABBV) accounts for about 1.40% of total assets, followed by Lockheed Martin Corp (LMT) and Bristol Myers Squibb Co (BMY). AbbVie Inc. (ABBV): Free Stock Analysis Report Designed to provide broad exposure to the Style Box - Large Cap Blend category of the market, the Franklin ... | Looking at individual holdings, Abbvie Inc (ABBV) accounts for about 1.40% of total assets, followed by Lockheed Martin Corp (LMT) and Bristol Myers Squibb Co (BMY). AbbVie Inc. (ABBV): Free Stock Analysis Report Designed to provide broad exposure to the Style Box - Large Cap Blend category of the market, the Franklin ... | Looking at individual holdings, Abbvie Inc (ABBV) accounts for about 1.40% of total assets, followed by Lockheed Martin Corp (LMT) and Bristol Myers Squibb Co (BMY). AbbVie Inc. (ABBV): Free Stock Analysis Report Designed to provide broad exposure to the Style Box - Large Cap Blend category of the market, the Franklin ... | Looking at individual holdings, Abbvie Inc (ABBV) accounts for about 1.40% of total assets, followed by Lockheed Martin Corp (LMT) and Bristol Myers Squibb Co (BMY). AbbVie Inc. (ABBV): Free Stock Analysis Report Designed to provide broad exposure to the Style Box - Large Cap Blend category of the market, the Franklin ... |
23,470 | 2022-04-19 00:00:00 UTC | Is First Trust Multi Cap Growth AlphaDEX ETF (FAD) a Strong ETF Right Now? | ABBV | https://www.nasdaq.com/articles/is-first-trust-multi-cap-growth-alphadex-etf-fad-a-strong-etf-right-now-1 | null | null | The First Trust Multi Cap Growth AlphaDEX ETF (FAD) made its debut on 05/08/2007, and is a smart beta exchange traded fund that provides broad exposure to the Style Box - All Cap Growth category of the market.
What Are Smart Beta ETFs?
Market cap weighted indexes were created to reflect the market, or a specific segmen... | Looking at individual holdings, Cheniere Energy, Inc. (LNG) accounts for about 0.65% of total assets, followed by Nucor Corporation (NUE) and Abbvie Inc. (ABBV). AbbVie Inc. (ABBV): Free Stock Analysis Report Representing 22.40% of the portfolio, the fund has heaviest allocation to the Information Technology sector; He... | Looking at individual holdings, Cheniere Energy, Inc. (LNG) accounts for about 0.65% of total assets, followed by Nucor Corporation (NUE) and Abbvie Inc. (ABBV). AbbVie Inc. (ABBV): Free Stock Analysis Report The NASDAQ AlphaDEX Multi Cap Growth Index is an enhanced which employs the AlphaDEX stock selection methodolog... | Looking at individual holdings, Cheniere Energy, Inc. (LNG) accounts for about 0.65% of total assets, followed by Nucor Corporation (NUE) and Abbvie Inc. (ABBV). AbbVie Inc. (ABBV): Free Stock Analysis Report The First Trust Multi Cap Growth AlphaDEX ETF (FAD) made its debut on 05/08/2007, and is a smart beta exchange ... | Looking at individual holdings, Cheniere Energy, Inc. (LNG) accounts for about 0.65% of total assets, followed by Nucor Corporation (NUE) and Abbvie Inc. (ABBV). AbbVie Inc. (ABBV): Free Stock Analysis Report The First Trust Multi Cap Growth AlphaDEX ETF (FAD) made its debut on 05/08/2007, and is a smart beta exchange ... |
23,471 | 2022-04-18 00:00:00 UTC | J&J (JNJ) to Set the Tone for Pharma Sector's Q1 Earnings | ABBV | https://www.nasdaq.com/articles/jj-jnj-to-set-the-tone-for-pharma-sectors-q1-earnings | null | null | We expect Johnson & Johnson JNJ to beat expectations when it reports first-quarter 2022 results on Apr 19, before market open. In the last-reported quarter, the company delivered an earnings surprise of 0.47%.
The healthcare bellwether’s performance has been pretty impressive, with the company exceeding earnings expect... | AbbVie ABBV with an Earnings ESP of +0.48% and a Zacks Rank #3. AbbVie’s stock has surged 22.2% in the past year. AbbVie topped earnings estimates in three of the last four quarters. | AbbVie ABBV with an Earnings ESP of +0.48% and a Zacks Rank #3. AbbVie’s stock has surged 22.2% in the past year. AbbVie topped earnings estimates in three of the last four quarters. | AbbVie ABBV with an Earnings ESP of +0.48% and a Zacks Rank #3. AbbVie’s stock has surged 22.2% in the past year. AbbVie topped earnings estimates in three of the last four quarters. | AbbVie topped earnings estimates in three of the last four quarters. AbbVie ABBV with an Earnings ESP of +0.48% and a Zacks Rank #3. AbbVie’s stock has surged 22.2% in the past year. |
23,472 | 2022-04-18 00:00:00 UTC | This High-Yielding Dividend Stock Has Raised Its Payout by 120% in Just 5 Years | ABBV | https://www.nasdaq.com/articles/this-high-yielding-dividend-stock-has-raised-its-payout-by-120-in-just-5-years | null | null | Dividend stocks can provide investors with recurring cash flow that they can use for just about any purpose. However, inflation can chip away at the value of a dividend over time. One way investors can offset that risk is by investing in companies that regularly increase their payouts.
One of the top dividend growth st... | Although AbbVie's dividend yield is 3.2% today, the table above shows how income can quickly rise by just hanging on to your investment. And while the company would recover from that, an investor screening for stocks with low payout ratios could have easily overlooked AbbVie. One of the top dividend growth stocks you c... | AbbVie has doubled its dividend payments in just five years Today, AbbVie pays investors a quarterly dividend of $1.41 per share (or $5.64 per share annualized), currently yielding 3.55%. One of the top dividend growth stocks you can invest in right now is healthcare company AbbVie (NYSE: ABBV). But if you had invested... | AbbVie has doubled its dividend payments in just five years Today, AbbVie pays investors a quarterly dividend of $1.41 per share (or $5.64 per share annualized), currently yielding 3.55%. One of the top dividend growth stocks you can invest in right now is healthcare company AbbVie (NYSE: ABBV). But if you had invested... | AbbVie has doubled its dividend payments in just five years Today, AbbVie pays investors a quarterly dividend of $1.41 per share (or $5.64 per share annualized), currently yielding 3.55%. One of the top dividend growth stocks you can invest in right now is healthcare company AbbVie (NYSE: ABBV). But if you had invested... |
23,473 | 2022-04-15 00:00:00 UTC | 3 Top Dividend Kings to Buy for the Long Haul | ABBV | https://www.nasdaq.com/articles/3-top-dividend-kings-to-buy-for-the-long-haul-0 | null | null | When it comes to finding stocks that pay a dividend, it's important for investors to focus on companies with strong business fundamentals. This helps ensure the dividend will be around for years to come. A good place to look for dividend stocks is the list of Dividend Kings. This title is bestowed upon any company that... | Focusing on immunology, hematologic oncology, neuroscience, aesthetics, and eye care, AbbVie has had a successful run as a public company, outpacing Abbott by approximately 67% since the spinoff. On the other hand, over the past three years, AbbVie has been growing revenue at the fastest pace of the three, making the c... | Johnson & Johnson (NYSE: JNJ) has increased its dividend for 59 consecutive years while Abbott Labs (NYSE: ABT) and AbbVie (NYSE: ABBV) have done so for 50. AbbVie AbbVie gets to claim its Dividend King status because of its history as part of Abbott Labs. Focusing on immunology, hematologic oncology, neuroscience, aes... | Johnson & Johnson (NYSE: JNJ) has increased its dividend for 59 consecutive years while Abbott Labs (NYSE: ABT) and AbbVie (NYSE: ABBV) have done so for 50. AbbVie AbbVie gets to claim its Dividend King status because of its history as part of Abbott Labs. Focusing on immunology, hematologic oncology, neuroscience, aes... | Johnson & Johnson (NYSE: JNJ) has increased its dividend for 59 consecutive years while Abbott Labs (NYSE: ABT) and AbbVie (NYSE: ABBV) have done so for 50. AbbVie AbbVie gets to claim its Dividend King status because of its history as part of Abbott Labs. Focusing on immunology, hematologic oncology, neuroscience, aes... |
23,474 | 2022-04-14 00:00:00 UTC | Sandoz Launches Generic Version Of Eyedrop In U.S. For Patients With Ocular Hypertension | ABBV | https://www.nasdaq.com/articles/sandoz-launches-generic-version-of-eyedrop-in-u.s.-for-patients-with-ocular-hypertension | null | null | (RTTNews) - Sandoz Inc., a generic and biosimilar medicines unit of French drug major Novartis AG(NVS), said that it has launched generic brimonidine tartrate/timolol maleate eyedrop in US for patients with ocular hypertension or high eye pressure. It is an AB-rated generic equivalent to AbbVie's COMBIGAN.
Brimonidine ... | It is an AB-rated generic equivalent to AbbVie's COMBIGAN. (RTTNews) - Sandoz Inc., a generic and biosimilar medicines unit of French drug major Novartis AG(NVS), said that it has launched generic brimonidine tartrate/timolol maleate eyedrop in US for patients with ocular hypertension or high eye pressure. Brimonidine ... | It is an AB-rated generic equivalent to AbbVie's COMBIGAN. (RTTNews) - Sandoz Inc., a generic and biosimilar medicines unit of French drug major Novartis AG(NVS), said that it has launched generic brimonidine tartrate/timolol maleate eyedrop in US for patients with ocular hypertension or high eye pressure. Brimonidine ... | It is an AB-rated generic equivalent to AbbVie's COMBIGAN. (RTTNews) - Sandoz Inc., a generic and biosimilar medicines unit of French drug major Novartis AG(NVS), said that it has launched generic brimonidine tartrate/timolol maleate eyedrop in US for patients with ocular hypertension or high eye pressure. Anyone can d... | It is an AB-rated generic equivalent to AbbVie's COMBIGAN. (RTTNews) - Sandoz Inc., a generic and biosimilar medicines unit of French drug major Novartis AG(NVS), said that it has launched generic brimonidine tartrate/timolol maleate eyedrop in US for patients with ocular hypertension or high eye pressure. Brimonidine ... |
23,475 | 2022-04-14 00:00:00 UTC | Noteworthy ETF Inflows: HDV, ABBV, MRK, PEP | ABBV | https://www.nasdaq.com/articles/noteworthy-etf-inflows%3A-hdv-abbv-mrk-pep | null | null | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares Core High Dividend ETF (Symbol: HDV) where we have detected an approximate $211.3 million dollar inflow -- that's a 2.3% increase week over week in outstanding units (from 83,600,000... | Among the largest underlying components of HDV, in trading today AbbVie Inc (Symbol: ABBV) is up about 1.2%, Merck & Co Inc (Symbol: MRK) is off about 0.3%, and PepsiCo Inc (Symbol: PEP) is lower by about 0.2%. For a complete list of holdings, visit the HDV Holdings page » The chart below shows the one year price perfo... | Among the largest underlying components of HDV, in trading today AbbVie Inc (Symbol: ABBV) is up about 1.2%, Merck & Co Inc (Symbol: MRK) is off about 0.3%, and PepsiCo Inc (Symbol: PEP) is lower by about 0.2%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel,... | Among the largest underlying components of HDV, in trading today AbbVie Inc (Symbol: ABBV) is up about 1.2%, Merck & Co Inc (Symbol: MRK) is off about 0.3%, and PepsiCo Inc (Symbol: PEP) is lower by about 0.2%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel,... | Among the largest underlying components of HDV, in trading today AbbVie Inc (Symbol: ABBV) is up about 1.2%, Merck & Co Inc (Symbol: MRK) is off about 0.3%, and PepsiCo Inc (Symbol: PEP) is lower by about 0.2%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel,... |
23,476 | 2022-04-14 00:00:00 UTC | Best Biotech Stocks To Buy Now? 5 To Know | ABBV | https://www.nasdaq.com/articles/best-biotech-stocks-to-buy-now-5-to-know | null | null | 5 Top Biotech Stocks To Watch Today
The stock market offers plenty of opportunities for investors. Some industries would still catch the attention of investors regardless of the broader market sentiment. A prime example would be biotech stocks. Now, why is that so? For starters, this is a high-risk, high-reward industr... | Biotech Stocks To Watch Right Now Turning Point Therapeutics Inc (NASDAQ: TPTX) Sierra Oncology Inc (NASDAQ: SRRA) AbbVie Inc (NYSE: ABBV) Halozyme Therapeutics, Inc. (NASDAQ: HALO) Crinetics Pharmaceuticals Inc (NASDAQ: CRNX) Turning Point Therapeutics Firstly, we have the clinical-stage biopharmaceutical company, Tur... | Biotech Stocks To Watch Right Now Turning Point Therapeutics Inc (NASDAQ: TPTX) Sierra Oncology Inc (NASDAQ: SRRA) AbbVie Inc (NYSE: ABBV) Halozyme Therapeutics, Inc. (NASDAQ: HALO) Crinetics Pharmaceuticals Inc (NASDAQ: CRNX) Turning Point Therapeutics Firstly, we have the clinical-stage biopharmaceutical company, Tur... | Biotech Stocks To Watch Right Now Turning Point Therapeutics Inc (NASDAQ: TPTX) Sierra Oncology Inc (NASDAQ: SRRA) AbbVie Inc (NYSE: ABBV) Halozyme Therapeutics, Inc. (NASDAQ: HALO) Crinetics Pharmaceuticals Inc (NASDAQ: CRNX) Turning Point Therapeutics Firstly, we have the clinical-stage biopharmaceutical company, Tur... | Biotech Stocks To Watch Right Now Turning Point Therapeutics Inc (NASDAQ: TPTX) Sierra Oncology Inc (NASDAQ: SRRA) AbbVie Inc (NYSE: ABBV) Halozyme Therapeutics, Inc. (NASDAQ: HALO) Crinetics Pharmaceuticals Inc (NASDAQ: CRNX) Turning Point Therapeutics Firstly, we have the clinical-stage biopharmaceutical company, Tur... |
23,477 | 2022-04-14 00:00:00 UTC | Is Trending Stock AbbVie Inc. (ABBV) a Buy Now? | ABBV | https://www.nasdaq.com/articles/is-trending-stock-abbvie-inc.-abbv-a-buy-now | null | null | AbbVie (ABBV) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.
Shares of this drugmaker have returned +1.9% over the past month versus the Zacks S&P 500 composite's +5.9% change. The Zacks ... | Conclusion The facts discussed here and much other information on Zacks.com might help determine whether or not it's worthwhile paying attention to the market buzz about AbbVie. AbbVie (ABBV) is one of the stocks most watched by Zacks.com visitors lately. The Zacks Large Cap Pharmaceuticals industry, to which AbbVie be... | Due to the size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, AbbVie is rated Zacks Rank #3 (Hold). AbbVie (ABBV) is one of the stocks most watched by Zacks.com visitors lately. The Zacks Large Cap Pharmaceuticals industry, to which AbbVie belongs, has gai... | Due to the size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, AbbVie is rated Zacks Rank #3 (Hold). AbbVie (ABBV) is one of the stocks most watched by Zacks.com visitors lately. The Zacks Large Cap Pharmaceuticals industry, to which AbbVie belongs, has gai... | Due to the size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, AbbVie is rated Zacks Rank #3 (Hold). AbbVie (ABBV) is one of the stocks most watched by Zacks.com visitors lately. The Zacks Large Cap Pharmaceuticals industry, to which AbbVie belongs, has gai... |
23,478 | 2022-04-14 00:00:00 UTC | Genmab (GMAB), AbbVie's Epcoritamab Successful in LBCL Study | ABBV | https://www.nasdaq.com/articles/genmab-gmab-abbvies-epcoritamab-successful-in-lbcl-study | null | null | Genmab A/S GMAB and AbbVie ABBV announced top-line data from the first cohort of a phase I/II study — EPCORE NHL-1 — evaluating its subcutaneous bispecific antibody candidate, epcoritamab (DuoBody-CD3xCD20), as a potential treatment for relapsed/refractory (r/r) large B-cell lymphoma (LBCL).
The phase I/II study evalua... | Genmab A/S GMAB and AbbVie ABBV announced top-line data from the first cohort of a phase I/II study — EPCORE NHL-1 — evaluating its subcutaneous bispecific antibody candidate, epcoritamab (DuoBody-CD3xCD20), as a potential treatment for relapsed/refractory (r/r) large B-cell lymphoma (LBCL). Based on the data from this... | Genmab A/S GMAB and AbbVie ABBV announced top-line data from the first cohort of a phase I/II study — EPCORE NHL-1 — evaluating its subcutaneous bispecific antibody candidate, epcoritamab (DuoBody-CD3xCD20), as a potential treatment for relapsed/refractory (r/r) large B-cell lymphoma (LBCL). Based on the data from this... | Genmab A/S GMAB and AbbVie ABBV announced top-line data from the first cohort of a phase I/II study — EPCORE NHL-1 — evaluating its subcutaneous bispecific antibody candidate, epcoritamab (DuoBody-CD3xCD20), as a potential treatment for relapsed/refractory (r/r) large B-cell lymphoma (LBCL). Based on the data from this... | Genmab A/S GMAB and AbbVie ABBV announced top-line data from the first cohort of a phase I/II study — EPCORE NHL-1 — evaluating its subcutaneous bispecific antibody candidate, epcoritamab (DuoBody-CD3xCD20), as a potential treatment for relapsed/refractory (r/r) large B-cell lymphoma (LBCL). Image Source: Zacks Investm... |
23,479 | 2022-04-13 00:00:00 UTC | AbbVie Announces Positive Results For Epcoritamab From Phase 1/2 Trial In Blood Cancer | ABBV | https://www.nasdaq.com/articles/abbvie-announces-positive-results-for-epcoritamab-from-phase-1-2-trial-in-blood-cancer | null | null | (RTTNews) - AbbVie (ABBV) and Genmab A/S (GMAB) announced topline results for Epcoritamab (DuoBody-CD3xCD20) from phase 1/2 trial in patients with Relapsed/Refractory Large B-cell Lymphoma. Epcoritamab is an an investigational subcutaneous bispecific antibody.
The study cohort included 157 patients with relapsed/refrac... | (RTTNews) - AbbVie (ABBV) and Genmab A/S (GMAB) announced topline results for Epcoritamab (DuoBody-CD3xCD20) from phase 1/2 trial in patients with Relapsed/Refractory Large B-cell Lymphoma. Epcoritamab is being co-developed by AbbVie and Genmab as part of the companies' broad oncology collaboration. The topline results... | (RTTNews) - AbbVie (ABBV) and Genmab A/S (GMAB) announced topline results for Epcoritamab (DuoBody-CD3xCD20) from phase 1/2 trial in patients with Relapsed/Refractory Large B-cell Lymphoma. Epcoritamab is being co-developed by AbbVie and Genmab as part of the companies' broad oncology collaboration. The study cohort in... | (RTTNews) - AbbVie (ABBV) and Genmab A/S (GMAB) announced topline results for Epcoritamab (DuoBody-CD3xCD20) from phase 1/2 trial in patients with Relapsed/Refractory Large B-cell Lymphoma. Epcoritamab is being co-developed by AbbVie and Genmab as part of the companies' broad oncology collaboration. The study cohort in... | (RTTNews) - AbbVie (ABBV) and Genmab A/S (GMAB) announced topline results for Epcoritamab (DuoBody-CD3xCD20) from phase 1/2 trial in patients with Relapsed/Refractory Large B-cell Lymphoma. Epcoritamab is being co-developed by AbbVie and Genmab as part of the companies' broad oncology collaboration. The study cohort in... |
23,480 | 2022-04-13 00:00:00 UTC | Halozyme to buy Antares Pharma in $960 mln deal | ABBV | https://www.nasdaq.com/articles/halozyme-to-buy-antares-pharma-in-%24960-mln-deal-0 | null | null | Adds details on deal, background
April 13 (Reuters) - Halozyme Therapeutics Inc HALO.O will buy specialty pharmaceutical company Antares Pharma Inc ATRS.O in a $960 million all-cash deal, the companies said on Wednesday.
Halozyme will pay $5.60 for each share of Antares Pharma, a premium of 49.7% to the company's last ... | The company has in the past licensed its technology, called Enhanze, to several major drugmakers including Pfizer PFE.N and AbbVie ABBV.N for drug development. The acquisition of Antares would give Halozyme access to a range of medicines, such as testosterone therapy Xyosted, that have been approved by the U.S. Food an... | The company has in the past licensed its technology, called Enhanze, to several major drugmakers including Pfizer PFE.N and AbbVie ABBV.N for drug development. Adds details on deal, background April 13 (Reuters) - Halozyme Therapeutics Inc HALO.O will buy specialty pharmaceutical company Antares Pharma Inc ATRS.O in a ... | The company has in the past licensed its technology, called Enhanze, to several major drugmakers including Pfizer PFE.N and AbbVie ABBV.N for drug development. Adds details on deal, background April 13 (Reuters) - Halozyme Therapeutics Inc HALO.O will buy specialty pharmaceutical company Antares Pharma Inc ATRS.O in a ... | The company has in the past licensed its technology, called Enhanze, to several major drugmakers including Pfizer PFE.N and AbbVie ABBV.N for drug development. Adds details on deal, background April 13 (Reuters) - Halozyme Therapeutics Inc HALO.O will buy specialty pharmaceutical company Antares Pharma Inc ATRS.O in a ... |
23,481 | 2022-04-12 00:00:00 UTC | Curis (CRIS) Down on FDA Partial Clinical Hold on Lymphoma Study | ABBV | https://www.nasdaq.com/articles/curis-cris-down-on-fda-partial-clinical-hold-on-lymphoma-study | null | null | Shares of Curis, Inc. CRIS were down 8.3% on Monday after the FDA placed a partial clinical hold on its TakeAim lymphoma study evaluating its IRAK4 kinase inhibitor, emavusertib (CA-4948).
The open-label, dose-escalating phase I/II study is evaluating emavusertib for treating patients with B-cell malignancies, both as ... | The open-label, dose-escalating phase I/II study is evaluating emavusertib for treating patients with B-cell malignancies, both as a monotherapy and in combination with J&J JNJ /AbbVie’s ABBV BTK inhibitor, Imbruvica (ibrutinib). AbbVie markets Imbruvica in partnership with J&J. AbbVie and J&J are conducting several st... | The open-label, dose-escalating phase I/II study is evaluating emavusertib for treating patients with B-cell malignancies, both as a monotherapy and in combination with J&J JNJ /AbbVie’s ABBV BTK inhibitor, Imbruvica (ibrutinib). AbbVie markets Imbruvica in partnership with J&J. AbbVie and J&J are conducting several st... | The open-label, dose-escalating phase I/II study is evaluating emavusertib for treating patients with B-cell malignancies, both as a monotherapy and in combination with J&J JNJ /AbbVie’s ABBV BTK inhibitor, Imbruvica (ibrutinib). AbbVie markets Imbruvica in partnership with J&J. AbbVie and J&J are conducting several st... | AbbVie and J&J are conducting several studies on Imbruvica to evaluate the drug alone or in combination in different patient segments. The open-label, dose-escalating phase I/II study is evaluating emavusertib for treating patients with B-cell malignancies, both as a monotherapy and in combination with J&J JNJ /AbbVie’... |
23,482 | 2022-04-12 00:00:00 UTC | BeiGene (BGNE) Brukinsa Superior to Imbruvica in Leukemia Study | ABBV | https://www.nasdaq.com/articles/beigene-bgne-brukinsa-superior-to-imbruvica-in-leukemia-study | null | null | BeiGene, Ltd. BGNE announced that the phase III study — ALPINE — evaluating its BTK inhibitor drug, Brukinsa (zanubrutinib), for treating relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), met its primary endpoint of superiority compared to AbbVie’s ABBV popular cancer ... | BeiGene, Ltd. BGNE announced that the phase III study — ALPINE — evaluating its BTK inhibitor drug, Brukinsa (zanubrutinib), for treating relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), met its primary endpoint of superiority compared to AbbVie’s ABBV popular cancer ... | Per the final response data from the ALPINE study, as assessed by an Independent Review Committee (IRC), Brukinsa demonstrated superiority over AbbVie’s Imbruvica in treating R/R CLL or SLL patients, measured by objective response rate (“ORR”). BeiGene, Ltd. BGNE announced that the phase III study — ALPINE — evaluating... | BeiGene, Ltd. BGNE announced that the phase III study — ALPINE — evaluating its BTK inhibitor drug, Brukinsa (zanubrutinib), for treating relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), met its primary endpoint of superiority compared to AbbVie’s ABBV popular cancer ... | Data from a previously completed interim analysis of the ALPINE data had demonstrated that Brukinsa was superior to AbbVie’s Imbruvica as measured by the investigator-assessed overall response rate. The safety profile of Brukinsa seemed to be better than AbbVie’s Imbruvica. BeiGene, Ltd. BGNE announced that the phase I... |
23,483 | 2022-04-12 00:00:00 UTC | AbbVie: Great Company, Future Upside Likely Weakened | ABBV | https://www.nasdaq.com/articles/abbvie%3A-great-company-future-upside-likely-weakened | null | null | AbbVie (ABBV) is a diversified research-based biopharmaceutical company operating globally. AbbVie's comprehensive product portfolio of therapies aims to cure some of the most complex and severe diseases in the world.
Following AbbVie’s acquisition of Allergan in 2020, the company further enriched its biopharmaceutical... | Following AbbVie’s acquisition of Allergan in 2020, the company further enriched its biopharmaceutical portfolio, solidifying its leading position in critical therapeutic areas such as aesthetics, neuroscience, eye care, women’s health, immunology, and hematologic oncology. AbbVie should continue to see its bottom line... | Latest Results: Strong Bottom Line Profits AbbVie’s latest results illustrated the company's ability to generate robust cash flows and a rich bottom line once again. With AbbVie's biopharmaceutical sales retaining a strong growth trajectory, management's Fiscal 2022 outlook included adjusted diluted EPS estimates in th... | With AbbVie's biopharmaceutical sales retaining a strong growth trajectory, management's Fiscal 2022 outlook included adjusted diluted EPS estimates in the range of $14 to $14.20, implying growth of 11% at the midpoint compared to Fiscal 2021. Dividend Growth Prospects Fused with its dividend growth track record prior ... | This illustrates how robust and diversified AbbVie’s portfolio is, with Allergan's acquisition once again proven very beneficial and timely. AbbVie (ABBV) is a diversified research-based biopharmaceutical company operating globally. AbbVie's comprehensive product portfolio of therapies aims to cure some of the most com... |
23,484 | 2022-04-12 00:00:00 UTC | AbbVie : Phase 2 Study Of Navitoclax Combination Shows Anti-Fibrosis Activity In Rare Blood Cancer | ABBV | https://www.nasdaq.com/articles/abbvie-%3A-phase-2-study-of-navitoclax-combination-shows-anti-fibrosis-activity-in-rare | null | null | (RTTNews) - AbbVie Inc. (ABBV) announced new data from a phase 2 trial of navitoclax in combination with ruxolitinib in patients with myelofibrosis.
The company said it was pleased about early results of navitoclax in combination with ruxolitinib that indicate its novel mechanism of action of inducing cell death may ca... | (RTTNews) - AbbVie Inc. (ABBV) announced new data from a phase 2 trial of navitoclax in combination with ruxolitinib in patients with myelofibrosis. AbbVie said it is currently recruiting for two Phase 3 trials of navitoclax in combination with ruxolitinib for the treatment of myelofibrosis that will enroll more than 5... | (RTTNews) - AbbVie Inc. (ABBV) announced new data from a phase 2 trial of navitoclax in combination with ruxolitinib in patients with myelofibrosis. AbbVie said it is currently recruiting for two Phase 3 trials of navitoclax in combination with ruxolitinib for the treatment of myelofibrosis that will enroll more than 5... | AbbVie said it is currently recruiting for two Phase 3 trials of navitoclax in combination with ruxolitinib for the treatment of myelofibrosis that will enroll more than 500 patients. (RTTNews) - AbbVie Inc. (ABBV) announced new data from a phase 2 trial of navitoclax in combination with ruxolitinib in patients with my... | AbbVie said it is currently recruiting for two Phase 3 trials of navitoclax in combination with ruxolitinib for the treatment of myelofibrosis that will enroll more than 500 patients. (RTTNews) - AbbVie Inc. (ABBV) announced new data from a phase 2 trial of navitoclax in combination with ruxolitinib in patients with my... |
23,485 | 2022-04-12 00:00:00 UTC | 3 Soaring Pharma Stocks -- Can They Keep Climbing? | ABBV | https://www.nasdaq.com/articles/3-soaring-pharma-stocks-can-they-keep-climbing | null | null | Are you hungry for stocks that can produce market-beating gains? If so, there are some increasingly popular entrees on the biopharmaceutical industry's menu that deserve your attention.
Each for reasons of their own, shares of Bristol Myers Squibb (NYSE: BMY), Vertex Pharmaceuticals (NASDAQ: VRTX), and AbbVie (NYSE: AB... | With Rinvoq and Skyrizi to offset upcoming Humira losses, AbbVie's Botox franchise could go a long way to lift its stock price over the next several years. Each for reasons of their own, shares of Bristol Myers Squibb (NYSE: BMY), Vertex Pharmaceuticals (NASDAQ: VRTX), and AbbVie (NYSE: ABBV) keep soaring to new all-ti... | Each for reasons of their own, shares of Bristol Myers Squibb (NYSE: BMY), Vertex Pharmaceuticals (NASDAQ: VRTX), and AbbVie (NYSE: ABBV) keep soaring to new all-time highs. AbbVie Shares of this pharma stock reached a new all-time high last fall and it's been climbing ever since. AbbVie shares have climbed 29% this ye... | Each for reasons of their own, shares of Bristol Myers Squibb (NYSE: BMY), Vertex Pharmaceuticals (NASDAQ: VRTX), and AbbVie (NYSE: ABBV) keep soaring to new all-time highs. AbbVie Shares of this pharma stock reached a new all-time high last fall and it's been climbing ever since. AbbVie shares have climbed 29% this ye... | Each for reasons of their own, shares of Bristol Myers Squibb (NYSE: BMY), Vertex Pharmaceuticals (NASDAQ: VRTX), and AbbVie (NYSE: ABBV) keep soaring to new all-time highs. AbbVie Shares of this pharma stock reached a new all-time high last fall and it's been climbing ever since. AbbVie shares have climbed 29% this ye... |
23,486 | 2022-04-12 00:00:00 UTC | Will AbbVie Stock Continue To Make New Highs? | ABBV | https://www.nasdaq.com/articles/will-abbvie-stock-continue-to-make-new-highs | null | null | The price of AbbVie stock (NYSE: ABBV) reached its all-time high of around $174 yesterday. It is up over 12% in a month, while it rose a stellar 63% over the last twelve months. This marks a significant outperformance over the broader markets, with the S&P 500 rising 10%. The recent spike can be attributed to upward re... | A couple of days back, AbbVie announced positive data from late-stage clinical trials of Vuity to treat blurry near vision. Overall, AbbVie has a great portfolio of drugs to counter the biosimilar competition for Humira going forward, and this is now being recognized by the markets, evident from the price appreciation.... | AbbVie (ABBV) Stock Return (Recent) Comparison With Peers Five-Day Return: AMGN highest at 3.7%; BMY lowest at 1.9% Ten-Day Return: AMGN highest at 5.8%; BMY lowest at 2.8% Twenty-One Day Return: ABBV highest at 12.4%; GILD lowest at 3.2% may have moved, 2020 has created many pricing discontinuities which can offer att... | Of 148 instances in the last nine years that ABBV stock saw a twenty-one-day increase of 12% or more, 101 resulted in ABBV stock rising over the subsequent one-month period (twenty-one trading days). This pattern suggests a higher chance of a rise in ABBV stock over the next five days, next ten days, and next month, li... | This pattern suggests a higher chance of a rise in ABBV stock over the next five days, next ten days, and next month, likely resulting in new highs for the stock. AbbVie (ABBV) Stock Return (Recent) Comparison With Peers Five-Day Return: AMGN highest at 3.7%; BMY lowest at 1.9% Ten-Day Return: AMGN highest at 5.8%; BMY... |
23,487 | 2022-04-11 00:00:00 UTC | Can AbbVie (ABBV) Keep the Earnings Surprise Streak Alive? | ABBV | https://www.nasdaq.com/articles/can-abbvie-abbv-keep-the-earnings-surprise-streak-alive | null | null | Have you been searching for a stock that might be well-positioned to maintain its earnings-beat streak in its upcoming report? It is worth considering AbbVie (ABBV), which belongs to the Zacks Large Cap Pharmaceuticals industry.
When looking at the last two reports, this drugmaker has recorded a strong streak of surpas... | It is worth considering AbbVie (ABBV), which belongs to the Zacks Large Cap Pharmaceuticals industry. For the most recent quarter, AbbVie was expected to post earnings of $3.29 per share, but it reported $3.31 per share instead, representing a surprise of 0.61%. Price and EPS Surprise For AbbVie, estimates have been tr... | It is worth considering AbbVie (ABBV), which belongs to the Zacks Large Cap Pharmaceuticals industry. For the most recent quarter, AbbVie was expected to post earnings of $3.29 per share, but it reported $3.31 per share instead, representing a surprise of 0.61%. Price and EPS Surprise For AbbVie, estimates have been tr... | It is worth considering AbbVie (ABBV), which belongs to the Zacks Large Cap Pharmaceuticals industry. For the most recent quarter, AbbVie was expected to post earnings of $3.29 per share, but it reported $3.31 per share instead, representing a surprise of 0.61%. Price and EPS Surprise For AbbVie, estimates have been tr... | It is worth considering AbbVie (ABBV), which belongs to the Zacks Large Cap Pharmaceuticals industry. For the most recent quarter, AbbVie was expected to post earnings of $3.29 per share, but it reported $3.31 per share instead, representing a surprise of 0.61%. Price and EPS Surprise For AbbVie, estimates have been tr... |
23,488 | 2022-04-11 00:00:00 UTC | Top Analyst Reports for Alphabet, Amazon & AbbVie | ABBV | https://www.nasdaq.com/articles/top-analyst-reports-for-alphabet-amazon-abbvie | null | null | Monday, April 11, 2022
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Alphabet Inc. (GOOGL), Amazon.com, Inc. (AMZN), and AbbVie Inc. (ABBV). These research reports have been hand-picked from the roughly... | If you want an email notification each time Sheraz publishes a new article, please click here>>> Today's Must Read Alphabet (GOOGL) Benefits From Cloud & Search Initiatives Prime Momentum & Growing AWS Adoption Benefit Amazon (AMZN) AbbVie's (ABBV) Pipeline & New Drugs Key to Long-Term Growth Featured Reports Walmart (... | If you want an email notification each time Sheraz publishes a new article, please click here>>> Today's Must Read Alphabet (GOOGL) Benefits From Cloud & Search Initiatives Prime Momentum & Growing AWS Adoption Benefit Amazon (AMZN) AbbVie's (ABBV) Pipeline & New Drugs Key to Long-Term Growth Featured Reports Walmart (... | (You can read the full research report on Abbvie here >>>) Other noteworthy reports we are featuring today include Walmart Inc. (WMT), Eli Lilly and Company (LLY), and Toyota Motor Corporation (TM). If you want an email notification each time Sheraz publishes a new article, please click here>>> Today's Must Read Alphab... | Today's Research Daily features new research reports on 16 major stocks, including Alphabet Inc. (GOOGL), Amazon.com, Inc. (AMZN), and AbbVie Inc. (ABBV). (You can read the full research report on Amazon here >>>) Shares of AbbVie have outperformed the Zacks Large Cap Pharmaceuticals industry over the past year (+69.1%... |
23,489 | 2022-04-11 00:00:00 UTC | Walgreens trial over its part in Florida opioid crisis set to begin | ABBV | https://www.nasdaq.com/articles/walgreens-trial-over-its-part-in-florida-opioid-crisis-set-to-begin | null | null | By Dietrich Knauth
April 11 (Reuters) - A jury trial accusing Walgreens Boots Alliance WBA.O of contributing to Florida's opioid addiction epidemic was set to begin on Monday after the pharmacy chain opted not to join a multimillion-dollar settlement by other defendants.
The state accuses Walgreens of poor oversight in... | In addition, drugmakers Teva Pharmaceutical Industries Ltd TEVA.TA agreed to will pay $194.8 million, Abbvie Inc's ABBV.N Allergan unit will pay $134.2 million and Endo International Plc ENDP.O $65 million. By Dietrich Knauth April 11 (Reuters) - A jury trial accusing Walgreens Boots Alliance WBA.O of contributing to F... | In addition, drugmakers Teva Pharmaceutical Industries Ltd TEVA.TA agreed to will pay $194.8 million, Abbvie Inc's ABBV.N Allergan unit will pay $134.2 million and Endo International Plc ENDP.O $65 million. By Dietrich Knauth April 11 (Reuters) - A jury trial accusing Walgreens Boots Alliance WBA.O of contributing to F... | In addition, drugmakers Teva Pharmaceutical Industries Ltd TEVA.TA agreed to will pay $194.8 million, Abbvie Inc's ABBV.N Allergan unit will pay $134.2 million and Endo International Plc ENDP.O $65 million. By Dietrich Knauth April 11 (Reuters) - A jury trial accusing Walgreens Boots Alliance WBA.O of contributing to F... | In addition, drugmakers Teva Pharmaceutical Industries Ltd TEVA.TA agreed to will pay $194.8 million, Abbvie Inc's ABBV.N Allergan unit will pay $134.2 million and Endo International Plc ENDP.O $65 million. By Dietrich Knauth April 11 (Reuters) - A jury trial accusing Walgreens Boots Alliance WBA.O of contributing to F... |
23,490 | 2022-04-11 00:00:00 UTC | Walgreens fed opioid addiction, Florida says as trial starts | ABBV | https://www.nasdaq.com/articles/walgreens-fed-opioid-addiction-florida-says-as-trial-starts | null | null | By Dietrich Knauth
April 11 (Reuters) - Walgreens Boots Alliance Inc WBA.O supplied billions of opioid pills to drug addicts and criminals, contributing to an addiction epidemic in Florida, a lawyer for the state said on Monday as a civil trial against the pharmacy chain got underway.
Walgreens filled one in four opioi... | Pharmacy chain rival CVS Health Corp CVS.N agreed to pay $484 million, while drugmakers Teva Pharmaceutical Industries Ltd TEVA.TA will pay $194.8 million, Abbvie Inc's ABBV.N Allergan unit will pay $134.2 million and Endo International Plc ENDP.O will pay $65 million. Walgreens filled one in four opioid prescriptions ... | Pharmacy chain rival CVS Health Corp CVS.N agreed to pay $484 million, while drugmakers Teva Pharmaceutical Industries Ltd TEVA.TA will pay $194.8 million, Abbvie Inc's ABBV.N Allergan unit will pay $134.2 million and Endo International Plc ENDP.O will pay $65 million. By Dietrich Knauth April 11 (Reuters) - Walgreens ... | Pharmacy chain rival CVS Health Corp CVS.N agreed to pay $484 million, while drugmakers Teva Pharmaceutical Industries Ltd TEVA.TA will pay $194.8 million, Abbvie Inc's ABBV.N Allergan unit will pay $134.2 million and Endo International Plc ENDP.O will pay $65 million. By Dietrich Knauth April 11 (Reuters) - Walgreens ... | Pharmacy chain rival CVS Health Corp CVS.N agreed to pay $484 million, while drugmakers Teva Pharmaceutical Industries Ltd TEVA.TA will pay $194.8 million, Abbvie Inc's ABBV.N Allergan unit will pay $134.2 million and Endo International Plc ENDP.O will pay $65 million. Walgreens filled one in four opioid prescriptions ... |
23,491 | 2022-04-10 00:00:00 UTC | 3 No-Brainer Warren Buffett Stocks to Buy Right Now | ABBV | https://www.nasdaq.com/articles/3-no-brainer-warren-buffett-stocks-to-buy-right-now | null | null | You don't earn the nickname "Oracle of Omaha" without doing some serious thinking along the way. Warren Buffett has studied businesses for decades. He's been highly successful doing so, amassing a multibillion-dollar fortune along the way.
With that kind of track record, it seems reasonable to expect that Buffett's por... | AbbVie Admittedly, Buffett isn't as big a fan of pharmaceutical stocks as he once was. AbbVie (NYSE: ABBV) looks like the best of the bunch. My view is that the main reason to buy AbbVie right now is its valuation. | AbbVie Admittedly, Buffett isn't as big a fan of pharmaceutical stocks as he once was. AbbVie (NYSE: ABBV) looks like the best of the bunch. My view is that the main reason to buy AbbVie right now is its valuation. | AbbVie Admittedly, Buffett isn't as big a fan of pharmaceutical stocks as he once was. AbbVie (NYSE: ABBV) looks like the best of the bunch. My view is that the main reason to buy AbbVie right now is its valuation. | Keith Speights owns AbbVie, Bank of America, and Berkshire Hathaway (B shares). AbbVie Admittedly, Buffett isn't as big a fan of pharmaceutical stocks as he once was. AbbVie (NYSE: ABBV) looks like the best of the bunch. |
23,492 | 2022-04-08 00:00:00 UTC | Best Stocks To Buy Now? 3 Health Care Stocks For Your List | ABBV | https://www.nasdaq.com/articles/best-stocks-to-buy-now-3-health-care-stocks-for-your-list | null | null | Are These The Best Health Care Stocks To Invest In This Month?
With growing geopolitical unrest, a hawkish Federal Reserve, and a shaky global economy, stocks seem to be under pressure. In theory, this would see health care stocks among other defensive stock market areas come into focus now. By and large, the current m... | On one hand, biotech giants like AbbVie (NYSE: ABBV) remain hard at work expanding their portfolios. In fact, Tilray’s unprecedented production platform supports over 20 brands that include comprehensive cannabis offerings, hemp-based foods, and alcoholic beverages. Irwin D. Simon, Tilray’s Chairman, and Chief Executiv... | On one hand, biotech giants like AbbVie (NYSE: ABBV) remain hard at work expanding their portfolios. Health Care Stocks To Buy [Or Sell] Today Tilray Inc. (NASDAQ: TLRY) Merck & Company Inc. (NYSE: MRK) BioXcel Therapeutics Inc. (NASDAQ: BTAI) Tilray Tilray is a medical cannabis company that is a leader in the cannabis... | On one hand, biotech giants like AbbVie (NYSE: ABBV) remain hard at work expanding their portfolios. With all this in mind, here are three top health care stocks to note in the stock market today. Health Care Stocks To Buy [Or Sell] Today Tilray Inc. (NASDAQ: TLRY) Merck & Company Inc. (NYSE: MRK) BioXcel Therapeutics ... | On one hand, biotech giants like AbbVie (NYSE: ABBV) remain hard at work expanding their portfolios. Health Care Stocks To Buy [Or Sell] Today Tilray Inc. (NASDAQ: TLRY) Merck & Company Inc. (NYSE: MRK) BioXcel Therapeutics Inc. (NASDAQ: BTAI) Tilray Tilray is a medical cannabis company that is a leader in the cannabis... |
23,493 | 2022-04-08 00:00:00 UTC | 3 Things About Pfizer That Smart Investors Know | ABBV | https://www.nasdaq.com/articles/3-things-about-pfizer-that-smart-investors-know | null | null | As one of the world's most discussed businesses, Pfizer (NYSE: PFE) needs little introduction. Thanks to sales of its coronavirus vaccine, Comirnaty, and its antiviral drug for coronavirus infections, Paxlovid, Pfizer's top line has positively exploded, with its trailing 12-month revenue popping by more than 99% over t... | The drop in market share might put the company in a slightly weaker position when it comes to attracting talent or financing acquisitions, but it probably isn't an existential threat. And, given that its annual free cash flow (FCF) has risen by 183% since the start of 2020, there's little reason to suspect that managem... | PFE Annual Revenue Estimates data by YCharts In a nutshell, the company is anticipated to bring in even more revenue next year than it did in 2021 -- and maybe even more than this year's projected sum of up to $102 billion -- but that's expected to be the high-water mark for a while. Its share of the global prescriptio... | Thanks to sales of its coronavirus vaccine, Comirnaty, and its antiviral drug for coronavirus infections, Paxlovid, Pfizer's top line has positively exploded, with its trailing 12-month revenue popping by more than 99% over the last three years, reaching a total of $81.2 billion. The dividend will keep growing While it... | Its share of the global prescription drug market may shrink As a major pharmaceutical business, Pfizer doesn't make medicines in a vacuum. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market. * They just revealed what they believe are the ten best stocks for inve... |
23,494 | 2022-04-08 00:00:00 UTC | Here's Why a Drop in Moderna's Revenue Wouldn't Be Catastrophic | ABBV | https://www.nasdaq.com/articles/heres-why-a-drop-in-modernas-revenue-wouldnt-be-catastrophic | null | null | The one big concern investors have about coronavirus-vaccine giant Moderna (NASDAQ: MRNA) is this: a potential drop in revenue. Moderna's only commercialized product right now is its coronavirus vaccine. The worry is that, eventually, when the pandemic shifts to endemic, people won't rush to be vaccinated. And as a res... | The one big concern investors have about coronavirus-vaccine giant Moderna (NASDAQ: MRNA) is this: a potential drop in revenue. So even if Moderna only has a couple of years of revenue around the 2021 level, it may be enough to ensure a bright future for the biotech company. And these couple of years at sky-high levels... | This chart below shows Moderna's coronavirus vaccine makes the list in the fourth spot. This chart shows mRNA product revenue rising from 2029 through the mid-2030s. It's still not clear exactly how much Moderna's coronavirus vaccine sales may decline in the next few years. | Moderna recently said it expects this-year's vaccine revenue to total at least $21 billion. Moderna's future The second chart gives us a look at what the future might bring for Moderna. This indicates that Moderna -- and others in the mRNA space -- could see a wave of revenue gains as products make it to market. | Moderna's only commercialized product right now is its coronavirus vaccine. The chart above indicates that all mRNA products may represent $21 billion in sales by 2024. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market. |
23,495 | 2022-04-08 00:00:00 UTC | These 3 Dividend ETFs Are a Retiree's Best Friend | ABBV | https://www.nasdaq.com/articles/these-3-dividend-etfs-are-a-retirees-best-friend-2 | null | null | Investing in exchange-traded funds can help retirees solve two challenges they might face in the golden years. Markets change, innovations bring new companies to the forefront, and the profitable companies of today may not be the profitable companies of tomorrow. First, it can ease the pain that comes from researching ... | Among the top holdings in the ETF's bucket of 51 stocks are a few Dividend Aristocrats -- including Warren Buffett favorites AbbVie, Chevron, and Kraft Heinz -- helping the fund deliver an annual dividend of $1.60 per share at a dividend yield of 3.65%, which is three times that of the S&P 500's 1.3% yield. A higher as... | Among the top holdings in the ETF's bucket of 51 stocks are a few Dividend Aristocrats -- including Warren Buffett favorites AbbVie, Chevron, and Kraft Heinz -- helping the fund deliver an annual dividend of $1.60 per share at a dividend yield of 3.65%, which is three times that of the S&P 500's 1.3% yield. Dividend ET... | Among the top holdings in the ETF's bucket of 51 stocks are a few Dividend Aristocrats -- including Warren Buffett favorites AbbVie, Chevron, and Kraft Heinz -- helping the fund deliver an annual dividend of $1.60 per share at a dividend yield of 3.65%, which is three times that of the S&P 500's 1.3% yield. Dividend ET... | Among the top holdings in the ETF's bucket of 51 stocks are a few Dividend Aristocrats -- including Warren Buffett favorites AbbVie, Chevron, and Kraft Heinz -- helping the fund deliver an annual dividend of $1.60 per share at a dividend yield of 3.65%, which is three times that of the S&P 500's 1.3% yield. Not only do... |
23,496 | 2022-04-08 00:00:00 UTC | Best Stocks for 2022: Up 20% This Year, AbbVie Is Doing Great | ABBV | https://www.nasdaq.com/articles/best-stocks-for-2022%3A-up-20-this-year-abbvie-is-doing-great | null | null | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
Editor’s note: This column is part of InvestorPlace.com’s Best Stocks for 2021 contest. Bob Ciura’s pick for the contest is AbbVie (NYSE:ABBV) stock.
Heading into 2022, I recommended investors take a closer look at pharmaceutical giant AbbVie (NYSE:ABBV) be... | Heading into 2022, I recommended investors take a closer look at pharmaceutical giant AbbVie (NYSE:ABBV) because the stock possessed several key factors that could make for a good investment. However, even if AbbVie stock does not continue to see its valuation multiple increase, its earnings-per-share growth and divide... | Finally, AbbVie stock also provided a high dividend yield, with regular dividend increases — AbbVie is one of just 66 Dividend Aristocrats, and one of just 40 Dividend Kings. Lastly, AbbVie’s global aesthetics portfolio grew revenue by 23% for the fourth quarter, due to 27% growth in global Botox revenue. However, even... | Finally, AbbVie stock also provided a high dividend yield, with regular dividend increases — AbbVie is one of just 66 Dividend Aristocrats, and one of just 40 Dividend Kings. Lastly, AbbVie’s global aesthetics portfolio grew revenue by 23% for the fourth quarter, due to 27% growth in global Botox revenue. However, even... | Finally, AbbVie stock also provided a high dividend yield, with regular dividend increases — AbbVie is one of just 66 Dividend Aristocrats, and one of just 40 Dividend Kings. However, even if AbbVie stock does not continue to see its valuation multiple increase, its earnings-per-share growth and dividends will provide ... |
23,497 | 2022-04-07 00:00:00 UTC | 2 Great Dividend Stocks to Buy Now to Help Tackle Inflation | ABBV | https://www.nasdaq.com/articles/2-great-dividend-stocks-to-buy-now-to-help-tackle-inflation | null | null | Wall Street turned its focus back to the possibility of higher interest rates as the Fed is indicating a more hawkish turn to help combat 40-year high inflation. The recently-released Fed minutes showed that it is leaning toward a 0.50% rate hike at its next meeting, while shrinking its balance sheet.
The yield on the ... | AbbVie ABBV AbbVie stock is in the midst of a gigantic run that began to kick into high gear last fall. ABBV is more diversified than ever and far less exposed to the success of one of the world’s top-selling drugs, which is crucial since Humira biosimilars are already available outside of the U.S. AbbVie acquired Alle... | Image Source: Zacks Investment Research ABBV stock is up 165% in the last five years, which includes a significant rough patch, to blow away the Large-Cap Pharma’s 75% and the S&P 500’s 100%. AbbVie ABBV AbbVie stock is in the midst of a gigantic run that began to kick into high gear last fall. ABBV is more diversified... | AbbVie ABBV AbbVie stock is in the midst of a gigantic run that began to kick into high gear last fall. ABBV is more diversified than ever and far less exposed to the success of one of the world’s top-selling drugs, which is crucial since Humira biosimilars are already available outside of the U.S. AbbVie acquired Alle... | AbbVie ABBV AbbVie stock is in the midst of a gigantic run that began to kick into high gear last fall. ABBV is more diversified than ever and far less exposed to the success of one of the world’s top-selling drugs, which is crucial since Humira biosimilars are already available outside of the U.S. AbbVie acquired Alle... |
23,498 | 2022-04-07 00:00:00 UTC | May 27th Options Now Available For AbbVie (ABBV) | ABBV | https://www.nasdaq.com/articles/may-27th-options-now-available-for-abbvie-abbv | null | null | Investors in AbbVie Inc (Symbol: ABBV) saw new options become available today, for the May 27th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ABBV options chain for the new May 27th contracts and identified one put and one call contract of particular interest.
The put contract ... | Of course, a lot of upside could potentially be left on the table if ABBV shares really soar, which is why looking at the trailing twelve month trading history for AbbVie Inc, as well as studying the business fundamentals becomes important. Below is a chart showing ABBV's trailing twelve month trading history, with the... | Below is a chart showing ABBV's trailing twelve month trading history, with the $175.00 strike highlighted in red: Considering the fact that the $175.00 strike represents an approximate 2% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the pos... | Below is a chart showing the trailing twelve month trading history for AbbVie Inc, and highlighting in green where the $165.00 strike is located relative to that history: Turning to the calls side of the option chain, the call contract at the $175.00 strike price has a current bid of $3.35. Below is a chart showing ABB... | At Stock Options Channel, our YieldBoost formula has looked up and down the ABBV options chain for the new May 27th contracts and identified one put and one call contract of particular interest. Below is a chart showing ABBV's trailing twelve month trading history, with the $175.00 strike highlighted in red: Considerin... |
23,499 | 2022-04-06 00:00:00 UTC | Is AbbVie Still a Buy After Its 50% Run-Up? | ABBV | https://www.nasdaq.com/articles/is-abbvie-still-a-buy-after-its-50-run-up | null | null | Pharmaceutical giant AbbVie (NYSE: ABBV) has been one of the market's hottest stocks, rising more than 50% over the past year. It should raise eyebrows, considering the S&P 500 is up just 13% in that time. Why has AbbVie done so well and is it too late to benefit from buying shares?
Fear not -- AbbVie's rise has been a... | The company's massive $63 billion acquisition of Allergan in 2020 diversified AbbVie by adding several new products to its portfolio, including cosmetic surgery brand Botox. For long-term investors, AbbVie's a proven blue-chip winner with a growing pipeline and a management intent on building for its next growth phase.... | Don't forget that AbbVie will still sell Humira; the loss of patent protection means generic brands will enter the market, but Humira has an established brand that doctors and patients trust. Analyst estimates expect an initial 6% drop in revenue for AbbVie next year, and then for the company to begin growing again in ... | This has long been on investors' minds, going back to the fall of 2021 when I covered AbbVie's share-price struggles and pointed the finger at fears over looming competition for Humira as a primary reason investors had cooled on the stock. Don't forget that AbbVie will still sell Humira; the loss of patent protection m... | Pharmaceutical giant AbbVie (NYSE: ABBV) has been one of the market's hottest stocks, rising more than 50% over the past year. Why has AbbVie done so well and is it too late to benefit from buying shares? Fear not -- AbbVie's rise has been a long time coming, and it's something that could have the legs to continue. |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.